WO1997001326A1 - Stable topical compositions - Google Patents

Stable topical compositions Download PDF

Info

Publication number
WO1997001326A1
WO1997001326A1 PCT/US1996/010940 US9610940W WO9701326A1 WO 1997001326 A1 WO1997001326 A1 WO 1997001326A1 US 9610940 W US9610940 W US 9610940W WO 9701326 A1 WO9701326 A1 WO 9701326A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
saturated
composition
mixtures
group
Prior art date
Application number
PCT/US1996/010940
Other languages
French (fr)
Inventor
Julie Ann Wagner
Joseph Michael Zukowski
Larry Richard Robinson
George Endel Deckner
Marie Antoinette Rinaldi
Victoria Claire Szymanski
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to EP96923465A priority Critical patent/EP0835095A1/en
Priority to MX9800188A priority patent/MX9800188A/en
Priority to AU63968/96A priority patent/AU6396896A/en
Priority to JP9504551A priority patent/JPH11508560A/en
Publication of WO1997001326A1 publication Critical patent/WO1997001326A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/342Alcohols having more than seven atoms in an unbroken chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39Derivatives containing from 2 to 10 oxyalkylene groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86Polyethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/007Preparations for dry skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations

Definitions

  • the present invention relates to stable, leave-on skin care cosmetic compositions containing an active ingredient.
  • it relates to stable, cosmetic, aqueous-containing compositions having gel networks, liquid crystalline phases, or both.
  • the aqueous phase of these compositions contains relatively- low levels of free water.
  • the water is believed to be bound as part of the gel network or liquid crystals.
  • active ingredients are currently known for treating various skin conditions. It is difficult to formulate many of these actives into cosmetically-elegant, oil-in-water systems because of stability, solubility, ionic strength, and other such formulation considerations. Representative of some of these active ingredients are materials such as salicylic acid, N- acetyl-L-cysteine, retinoic acid, phytic acid, and their pharmaceutically- acceptable salts.
  • compositions containing salicylic acid, N- acetyl-L-cysteine, and retinoic acid are known in the art.
  • Salicylic acid and retinoic acid are keratoylic agents which are believed to help remove keratin plugs and to aid the skin's exfoliation process.
  • These materials are also known for their anti-acne and anti-skin aging benefits. See C. Huber et al., Arch. Derm Res. 257, pp. 293-297, 1977; U.S. Patent No. 4,888,342, to Kligman, issued December 19, 1989; U.S. Patent No. 4,877,805, to Kligman, Issued October 31, 1989; PCT Application No.
  • compositions of the present invention are well-suited for formulating and delivering a wide variety of active ingredients to the skin. Without being limited by theory, it is believed that these compositions contain gel network structures, liquid crystal structure, or both. It is believed that these gel networks and liquid crystals tend to bind the available water in the composition, thereby rendering the water less available for contributing to the instability and decomposition of the active ingredients. It is also found that these compositions are well-suited for carrying a high electrolyte concentration, making them ideal for delivering a wide range of ionic and other highly polar materials, e.g., zinc oxide, polar solvents.
  • (C) from about 0.05 % to about 10% of a hydrophilic surfactant selected from the group consisting of anionic surfactants, cationic surfactants, zwitterionic surfactants, amphoteric surfactants, and mixtures thereof; and (D) from about 25% to about 98.949% water.
  • a hydrophilic surfactant selected from the group consisting of anionic surfactants, cationic surfactants, zwitterionic surfactants, amphoteric surfactants, and mixtures thereof.
  • compositions of the present invention are useful for moisturizing and hydrating the skin and for depositing active ingredients onto the skin.
  • These compositions are in the form of oil-in-water emulsions whereby the oil phase and the water phase can contain, in addition to the essential components described herein, a variety of ingredients known in the art.
  • These compositions are in the form of topical, leave-on compositions.
  • compositions which are oil-in-water emulsions, comprising:
  • (C) from about 0.05 % to about 10% of a hydrophilic surfactant selected from the group consisting of anionic surfactants, cationic surfactants, zwitterionic surfactants, amphoteric surfactants, and mixtures thereof; and
  • the ratio of component (B) to component (C) is from about 20:1 to about 1:1, preferably from about 10:1 to about 1:1, more preferably from about 5:1 to about 1:1, and even more preferably about 3:1. These ratios allow for the formation of lamellar liquid crystalline phases, which contribute to the physical and chemical stability of the composition at temperatures from about -10°C to about 50°C.
  • compositions of the present invention have complex rheological characteristics. These compositions have physical properties characteristic of oil-in-water emulsions, liquid crystals, and crystalline gel networks. Without being limited by theory, it is believed that these compositions have low levels of free water, such that most of the water is bound up with liquid crystals or gel networks. It is found that these compositions are useful as vehicles for compositions which are labile in aqueous solution or dispersion. It is also found that these compositions are useful for formulating actives which present a high electrolyte load for the composition, i.e. actives which are ionic or highly polar.
  • the oil-in-water emulsions herein have desirable aesthetic and elegant properties, such as a rich and creamy, yet non-greasy, skin feel. These emulsions can span a broad range of consistencies from thin lotions to heavy creams. These emulsions typically have viscosities ranging from about 100 cps to about 500,000 cps, preferably from about 3,000 cps to about 200,000 cps, more preferably from about 5000 cps to about 150,000 cps, and even more preferably from about 5000 cps to about 100,000 cps, as measured at a temperature of 25°C with a Brookfield Synchro-Lectric Viscometer Model D.
  • the oil-in-water emulsion compositions can span a wide range of pH values. Even though buffers can be utilized to help maintain the pH of the emulsion compositions, these are not required components, but are merely optional ingredients.
  • compositions of the present invention comprise a safe and effective amount of one or more active ingredients or pharmaceutically acceptable salts thereof.
  • safe and effective amount means an amount of an active ingredient high enough to modify the condition to be treated or to deliver the desired skin benefit, but low enough to avoid serious side effects, at a reasonable benefit to risk ratio within the scope of sound medical judgement. What is a safe and effective amount of the active ingredient will vary with the specific active, the ability of the active to penetrate through the skin, the age, health condition, and skin condition of the user, and other like factors.
  • salts any of the commonly-used salts that are suitable for use in contact with the tissues of humans without undue toxicity, irritation, incompatibility, instability, irritation, allergic response, and the like.
  • the actives of the present invention comprise from about 0.001% to about 20%, preferably from about 0.01% to about 10%, and more preferably from about 0.025% to about 5% by weight of the composition.
  • the actives useful herein can be categorized by their therapeutic benefit or their postulated mode of action. However, it is to be understood that the actives useful herein can in some instances provide more than one therapeutic benefit or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit the active to that particular application or applications Iisted. Also, pharmaceutically-acceptable salts of these materials are useful herein. The following actives which preferably have the above outlined solubility parameters are useful in the compositions of the present invention.
  • Anti-Acne Actives examples include the keratolytics such as salicylic acid (o-hydroxybenzoic acid), derivatives of salicylic acid such as 5-octanoyl salicylic acid, and resorcinol; retinoids such as retinoic acid and its derivatives (e.g., cis and trans); sulfur- containing D and L amino acids and their derivatives and salts, particularly their N-acetyl derivatives, a preferred example of which is N-acetyl-L- cysteine; lipoic acid; antibiotics and antimicrobials such as benzoyl peroxide, octopirox, tetracycline, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'-trichlorobanilide, azelaic acid and its derivatives, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, ethy
  • keratolytics such as
  • Anti-Wrinkle and Anti-Skin Atrophy Actives examples include retinoic acid and its derivatives (e.g., cis and trans); salicylic acid and derivatives thereof; sulfur-containing D and L amino acids and their derivatives and salts, particularly the N-acetyl derivatives, a preferred example of which is N-acetyl L-cysteine; thiols, eg. ethane thiol; alpha-hydroxy acids, e.g. glycolic acid, and lactic acid; phytic acid, lipoic acid; lysophosphatidic acid, and skin peel agents (e.g., phenol and the like).
  • retinoic acid and its derivatives e.g., cis and trans
  • salicylic acid and derivatives thereof sulfur-containing D and L amino acids and their derivatives and salts, particularly the N-acetyl derivatives, a preferred example of which is N-acetyl L-cysteine
  • thiols e
  • Non-Steroidal Anti-Inflammatory Actives include the following categories: propionic acid derivatives; acetic acid derivatives; fenamic acid derivatives; biphenylcarboxylic acid derivatives; and oxicams. All of these NSAIDS are fully described in the U.S. Patent 4,985,459 to Sunshine et al., issued January 15, 1991, incorporated by reference herein.
  • NSAIDS examples include acetyl salicylic acid, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen and bucloxic acid.
  • steroidal anti-inflammatory drugs including hydrocortisone and the like.
  • Topical Anesthetics examples include benzocaine, lidocaine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine, phenol, and pharmaceutically acceptable salts thereof.
  • Artificial Tanning Agents and Accelerators examples include dihydroxyacetone, tyrosine, tyrosine esters such as ethyl tyrosinate, and phospho-DOPA.
  • Antimicrobial and Antifungal Actives examples include ⁇ -lactam drugs, quinolone drugs, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amikacin, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'-trichlorobanilide, phenoxyethanol, phenoxy propanol, phenoxyisopropanol, doxycycline, capreomycin, chlorhexidine, chlortetracycline, oxytetracycline, clindamycin, ethambutol, hexamidine isethionate, metronidazole, pentamidine, gentamicin, kanamycin, lineomycin, methacycline, methenamine, minocycline, neomycin, netilmicin, paromomycin, streptomycin, tobramycin, miconazole, tetra
  • Sunscreening Actives Also useful herein are sunscreening agents.
  • a wide variety of sunscreening agents are described in U.S. Patent No. 5,087,445, to Haffey et al., issued February 11, 1992; U.S. Patent No. 5,073,372, to Turner et al., issued December 17, 1991; U.S. Patent No. 5,073,371, to Turner et al. issued December 17, 1991; and Segarin, et al., at Chapter VIII, pages 189 et seq., of Cosmetics Science and Technology, all of which are incorporated herein by reference in their entirety.
  • sunscreening agents disclosed therein have, in a single molecule, two distinct chromophore moieties which exhibit different ultra ⁇ violet radiation abso ⁇ tion spectra.
  • One of the chromophore moieties absorbs predominantly in the UVB radiation range and the other absorbs strongly in the UVA radiation range.
  • sunscreens include those selected from the group consisting of 4-N,N-(2-ethylhexyl)methylaminobenzoic acid ester of 2,4- dihydroxybenzophenone, 4-N,N-(2-ethylhexyl)methylaminobenzoic acid ester with 4-hydroxydibenzoylmethane, 4-N.N- (2-ethylhexyl)methylamino- benzoic acid ester of 2-hydroxy-4-(2-hydroxyethoxy)benzophenone, 4-N.N- (2-ethylhexyl)-methylaminobenzoic acid ester of 4-(2-hydroxyeth- oxy)dibenzoylmethane, and mixtures thereof.
  • the sunscreens can comprise from about 0.5% to about 20% of the compositions useful herein. Exact amounts will vary depending upon the sunscreen chosen and the desired Sun Protection Factor (SPF). SPF is a commonly used measure of photoprotection of a sunscreen against erythema. See Federal Register. Vol. 43, No. 166, pp. 38206-38269, August 25, 1978, which is incorporated herein by reference in its entirety.
  • actives useful herein include those selected from the group consisting of salicylic acid, 3-hydroxy benzoic acid, 4- hydroxy benzoic acid, acetyl salicylic acid, 2-hydroxybutanoic acid, 2- hydroxypentanoic acid, 2-hydroxyhexanoic acid, cis-retinoic acid, trans- retinoic acid, N-acetyl L-cysteine, lipoic acid, azelaic acid, arachidonic acid, benzoylperoxide, tetracycline, ibuprofen, naproxen, hydrocortisone, acetominophen, resorcinol, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'- trichlorocarbanilide, octopirox, lidocaine hydrochloride, clotrimazole, miconazole,
  • actives useful herein include those selected from the group consisting of salicylic acid, acetyl salicylic acid, cis- retinoic acid, trans-retinoic acid, N-acetyl-L-cysteine, lipoic acid, azelaic acid, tetracycline, ibuprofen, naproxen, acetominophen, hydrocortisone, resorcinol, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4'- trichloro- -hydroxy diphenyl ether, 3,4,4'-trichlorocarbanilide, octopirox, 2- phenylbenzimidazole-5-sulfonic acid, dihydroxyacetone, and mixtures thereof.
  • actives useful herein include those selected from the group consisting of salicylic acid, cis-retinoic acid, trans- retinoic acid, N-acetyl L-cysteine, azelaic acid, lipoic acid, resorcinol, ibuprofen, naproxen, hydrocortisone, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'- trichlorocarbanilide, 2-phenylbenzimidazole-5-sulfonic acid, dihydroxyacetone, and mixtures thereof.
  • the present invention also comprises from about 1% to about 20%, preferably from about 1% to about 10%, more preferably from about 3% to about 9%, of a stable, hydrophobic, structuring agent selected from the group consisting of saturated C-
  • a stable, hydrophobic, structuring agent selected from the group consisting of saturated C-
  • structuring agents are useful to assist in the formation of the rheological characteristic of the composition which contribute to the hydrolytic stability of the composition of the present invention.
  • structuring agents assist in the formation of the liquid crystalline gel network structures.
  • the preferred structuring agents of the present invention are selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmitic acid, the polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 5 ethylene oxide units, the polyethylene glycol ether of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof.
  • More preferred structuring agents of the present invention are selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol, the polyethylene glycol ether of stearyl alcohol having an average of about 2 ethylene oxide units (steareth-2), the polyethylene glycol ether of cetyl alcohol having an average of about 2 ethylene oxide units, and mixtures thereof.
  • Even more preferred structuring agents are selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol, steareth- 2, and mixtures thereof. Most preferred is steareth-2, available under the tradename of Brij® 72 from ICI Americas.
  • compositions of the present invention comprise from about 0.05% to about 10%, preferably from about 1% to about 6%, and more preferably from about 1 % to about 3% of at least one hydrophilic surfactant which can disperse the hydrophobic materials in the water phase.
  • the surfactant at a minimum, must be hydrophilic enough to disperse in water.
  • the surfactants useful herein can include any of a wide variety of cationic, anionic, zwitterionic, and amphoteric surfactants disclosed in prior patents and other references. See McCutcheon's, Detergents and Emulsifiers. North American Edition (1986), published by Allured Publishing Co ⁇ oration; U.S. Patent No. 5,011,681 to Ciotti et al., issued April 30, 1991; U.S. Patent No. 4,421,769 to Dixon et al., issued December 20, 1983; and U.S. Patent No. 3,755,560 to Dickert et al., issued August 28, 1973; these four references are incorporated herein by reference in their entirety.
  • the exact surfactant chosen will depend upon the pH of the composition and the other components present.
  • cationic surfactants especially dialkyi quaternary ammonium compounds.
  • a wide variety of cationic surfactants useful herein are disclosed in U.S. Patent No. 5,151,209, to McCall et al., issued September 29, 1992; U.S. Patent No. 5,151,210, to Steuri et al., issued September 29, 1992; U.S. Patent No. 5,120,532, to Wells et al., issued June 9, 1992; U.S. Patent No. 4,387,090, to Bolich, issued June 7, 1983;; U.S. Patent 3,155,591, Spotifyr, issued November 3, 1964; U.S. Patent No.
  • cationic surfactants useful herein include cationic ammonium salts such as those having the formula:
  • R-j is an alkyl group having from about 12 to about 30 carbon atoms, or an aromatic, aryl or alkaryl groups having from about 12 to about 30 carbon atoms
  • R2, R3, and R4 are independently selected from hydrogen, an alkyl group having from about 1 to about 22 carbon atoms, or aromatic, aryl or alkaryl groups having from about 12 to about 22 carbon atoms
  • X is any compatible anion, preferably selected from the group consisting of chloride, bromide, iodide, acetate, phosphate, nitrate, sulfate, methyl sulfate, ethyl sulfate, tosylate, lactate, citrate, glycolate, and mixtures thereof.
  • R-j is an alkyl group having from about 12 to about 22 carbon atoms
  • R2 is selected from H or an alkyl group having from about 1 to about 22 carbon atoms
  • R3 and R4 are independently selected from H or an alkyl group having from about 1 to about 3 carbon atoms
  • X is as described previously.
  • R-j is an alkyl group having from about 12 to about 22 carbon atoms
  • R2, R3. and R4 are selected from H or an alkyl group having from about 1 to about 3 carbon atoms
  • X is as described previously.
  • R ⁇ j is alternatively R5CONH-(CH2)rr.
  • R5 is an alkyl group having from about 12 to about 22 carbon atoms
  • n is an integer from about 2 to about 6, more preferably from about 2 to about 4, and most preferably from about 2 to about 3.
  • Nonlimiting examples of these cationic emulsifiers include stearamidopropyl PG-dimonium chloride phosphate, behenamidopropyl PG dimonium chloride, stearamidopropyl ethyldimonium ethosulfate, stearamidopropyl dimethyl (myristyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosylate, stearamidopropyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate, and mixtures thereof.
  • behenamidopropyl PG dimonium chloride is especially preferred.
  • Nonlimiting examples of quatemary ammonium salt cationic surfactants include those selected from the group consisting of cetyl ammonium chloride, cetyl ammonium bromide, lauryl ammonium chloride, lauryl ammonium bromide, stearyl ammonium chloride, stearyl ammonium bromide, cetyl dimethyl ammonium chloride, cetyl dimethyl ammonium bromide, lauryl dimethyl ammonium chloride, lauryl dimethyl ammonium bromide, stearyl dimethyl ammonium bromide, cetyl trimethyl ammonium chloride, cetyl trimethyl ammonium bromide, lauryl trimethyl ammonium chloride, lauryl trimethyl ammonium bromide, stearyl trimethyl ammonium bromide, lauryl trimethyl ammonium chloride, lauryl trimethyl ammonium bromide, stearyl trimethyl ammonium bromide, lauryl trimethyl ammonium chloride, lauryl
  • Additional quaternary ammonium salts include those wherein the C-J2 to C30 alkyl carbon chain is derived from a tallow fatty acid or from a coconut fatty acid.
  • tallow refers to an alkyl group derived from tallow fatty acids (usually hydrogenated tallow fatty acids), which generally have mixtures of alkyl chains in the C-jg to C-j ⁇ range.
  • coconut refers to an alkyl group derived from a coconut fatty acid, which generally have mixtures of alkyl chains in the C ⁇
  • Examples of quaternary ammonium salts derived from these tallow and coconut sources include ditallow dimethyl ammonium chloride, ditallow dimethyl ammonium methyl sulfate, di(hydrogenated tallow) dimethyl ammonium chloride, di(hydrogenated tallow) dimethyl ammonium acetate, ditallow dipropyl ammonium phosphate, ditallow dimethyl ammonium nitrate, di(coconutalkyl)dimethyl ammonium chloride, di(coconutalkyl)dimethyl ammonium bromide, tallow ammonium chloride, coconut ammonium chloride, stearamidopropyl PG-dimonium chloride phosphate, stearamidopropyl ethyldimonium ethosulfate, stearamidopropyl dimethyl (myristyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosy
  • More preferred cationic surfactants are those selected from the group consisting of behenamidopropyl PG dimonium chloride, dilauryl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, dimyristyl dimethyl ammonium chloride, dipalmityl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, stearamidopropyl PG-dimonium chloride phosphate, stearamidopropyl ethyldiammonium ethosulfate, stearamidopropyl dimethyl (myristyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosylate, stearamidopropyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate, and mixtures thereof.
  • Most preferred cationic surfactants are those selected from the group consisting of behenamidopropyl PG dimonium chloride, dilauryl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, dimyristyl dimethyl ammonium chloride, dipalmityl dimethyl ammonium chloride, and mixtures thereof.
  • a preferred combination of cationic surfactant and structuring agent is behenamidopropyl PG dimonium chloride and/or behenyl alcohol, wherein the ratio is preferably optimized to maintained to enhance physical and chemical stability, especially when such a combination contains ionic and/or highly polar solvents. This combination is especially useful for delivery of sunscreening agents such as zinc oxide and octyl methoxycinnamate.
  • anionic surfactants are also useful herein. See, e.g., U.S. Patent No. 3,929,678, to Laughlin et al., issued December 30, 1975, which is incorporated herein by reference in its entirety.
  • anionic surfactants include the alkoyl isethionates, and the alkyl and alkyl ether sulfates.
  • the alkoyl isethionates typically have the formula RCO-OCH 2 CH 2 SO 3 M wherein R is alkyl or alkenyl of from about 10 to about 30 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium and triethanolamine.
  • Nonlimiting examples of these isethionates include those alkoyl isethionates selected from the group consisting of ammonium cocoyl isethionate, sodium cocoyl isethionate, sodium lauroyl isethionate, sodium stearoyl isethionate, and mixtures thereof.
  • alkyl and alkyl ether sulfates typically have the respective formulae ROSO3M and RO(C 2 H 4 O) ⁇ SO 3 M, wherein R is alkyl or alkenyl of from about 10 to about 30 carbon atoms, x is from about 1 to about 10, and M is a water-soluble cation such as ammonium, sodium, potassium and triethanolamine.
  • R alkyl or alkenyl of from about 10 to about 30 carbon atoms
  • x is from about 1 to about 10
  • M is a water-soluble cation such as ammonium, sodium, potassium and triethanolamine.
  • anionic surfactants are the water-soluble salts of the organic, sulfuric acid reaction products of the general formula:
  • R ⁇ SOg-M wherein R 1 is chosen from the group consisting of a straight or branched chain, saturated aliphatic hydrocarbon radical having from about 8 to about 24, preferably about 10 to about 16, carbon atoms; and M is a cation.
  • Still other anionic synthetic surfactants include the class designated as succinamates, olefin sulfonates having about 12 to about 24 carbon atoms, and b-alkyloxy alkane sulfonates. Examples of these materials are sodium lauryl sulfate and ammonium lauryl sulfate.
  • soaps i.e. alkali metal salts, e.g., sodium or potassium salts
  • fatty acids typically having from about 8 to about 24 carbon atoms, preferably from about 10 to about 20 carbon atoms.
  • the fatty acids used in making the soaps can be obtained from natural sources such as, for instance, plant or animal-derived glycerides (e.g., palm oil, coconut oil, soybean oil, castor oil, tallow, lard, etc.)
  • the fatty acids can also be synthetically prepared. Soaps are described in more detail in U.S. Patent No. 4,557,853, cited above.
  • amphoteric and zwitterionic surfactants are also useful herein.
  • amphoteric and zwitterionic surfactants which can be used in the compositions of the present invention are those which are broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical can be straight or branched chain and wherein one of the aliphatic substituents contains from about 8 to about 22 carbon atoms (preferably C ⁇ - C-j ⁇ ) and one contains an anionic water solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate.
  • alkyl imino acetates examples are alkyl imino acetates, and iminodialkanoates and aminoalkanoates of the formulas RN[CH 2 ) m CO 2 M] 2 and RNH(CH 2 ) m CO 2 M wherein m is from 1 to 4, R is a C8-C22 alkyl or alkenyl, and M is H, alkali metal, alkaline earth metal ammonium, or alkanolammonium. Also included are imidazolinium and ammonium derivatives.
  • amphoteric surfactants include sodium 3-dodecyl-aminopropionate, sodium 3-dodecylaminopro ⁇ ane sulfonate, N-alkyltaurines such as the one prepared by reacting dodecylamine with sodium isethionate according to the teaching of U.S. Patent 2,658,072 which is inco ⁇ orated herein by reference in its entirety; N-higher alkyl aspartic acids such as those produced according to the teaching of U.S. Patent 2,438,091 which is inco ⁇ orated herein by reference in its entirety; and the products sold under the trade name "Miranol" and described in U.S.
  • Patent 2,528,3708 which is inco ⁇ orated herein by reference in its entirety.
  • Other examples of useful amphoterics include phosphates, such as coamidopropyl PG-dimonium chloride phosphate (commercially available as Monaquat PTC, from Mona Co ⁇ .).
  • amphoteric or zwitterionic surfactants are the betaines.
  • betaines include the higher alkyl betaines, such as coco dimethyl carboxymethyl betaine, lauryl dimethyl carboxymethyl betaine, lauryl dimethyl alphacarboxyethyl betaine, cetyl dimethyl carboxymethyl betaine, cetyl dimethyl betaine (available as Lonzaine 16SP from Lonza Co ⁇ .), lauryl bis-(2-hydroxyethyl) carboxymethyl betaine, stearyl bis-(2-hydroxypropyl) carboxymethyl betaine, oleyl dimethyl gamma- -carboxypropyl betaine, lauryl bis-(2-hydroxypropyl)alpha-carboxyethyl betaine, coco dimethyl sulfopropyl betaine, stearyl dimethyl sulfopropyl betaine, lauryl dimethyl sulfoethyl betaine, lauryl bis-(2-hydroxyethyl be
  • amphoteric and zwitterionic surfactants include the sultaines and hydroxysultaines such as cocamidopropyl hydroxysultaine (available as Mirataine CBS from Rhone-Poulenc), and the alkanoyl sarcosinates corresponding to the formula RCON(CH 3 )CH 2 CH 2 CO2M wherein R is alkyl or alkenyl of about 10 to about 20 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium and trialkanolamine (e.g., triethanolamine), a preferred example of which is sodium lauroyl sarcosinate.
  • sultaines and hydroxysultaines such as cocamidopropyl hydroxysultaine (available as Mirataine CBS from Rhone-Poulenc)
  • alkanoyl sarcosinates corresponding to the formula RCON(CH 3 )CH 2 CH 2 CO2M wherein R is alkyl or al
  • compositions of the present invention comprise from about 25% to about 98.949%, more preferably from about 65% to about 95%, and most preferably from about 70% to about 90% water.
  • Each of the water and oil phases of the emulsions can comprise a wide variety of optional components. Typical of such optional components are:
  • compositions of the present invention comprise from about 0.1% to about 25%, preferably from about 0.1% to about 15%, and more preferably from about 6% to about 10% of an alkoxylated alcohol and/or alkoxylated polyol.
  • the alkoxylated alcohols and polyols useful herein generally are hydrophobic, having a solubility in water of less than about 1 gram per about 100 grams of water at 25°C. Preferably, these solvents have a minimum of 10-20 moles of propylene oxide. These compounds are typically formulated into the oil phase of the oil-in-water emulsions as described in the Examples below. Mixtures of alkoxylated alcohols and polyols can be used herein.
  • the alkoxylated alcohols useful herein can be described by the following general formula:
  • R— O (CHCH 2 O) n H X wherein R is selected from the group consisting of alcohols, polyols, diols, and mixtures thereof, having a chainlength of from about 2 to about 30 carbon atoms; n is an integer from about 3 to about 40; X is selected from the group consisting of hydrogen, methyl, ethyl, propyl, and mixtures thereof.
  • R is selected from the group consisting of alcohols, polyols, diols, or mixtures thereof, having a chainlength of from about 4 to about 20 carbon atoms; X is methyl; and n is an integer from about 6 to about 35. More preferably R is selected from the group consisting of alcohols, polyols, diols, or mixtures thereof, having a chainlength of from about 4 to about 18 carbon atoms; X is methyl; and n is an integer from about 10 to about 20.
  • Nonlimiting examples of classes of alkoxylated alcohols useful herein include propoxylated and butoxylated ethers of alcohols and polyols. These compounds can be described as PPG and PBG alkyl ethers wherein the PPG and PBG are commonly used designations for polypropylene glycol and polybutylene glycol, respectively. The average number of PPG or PBG groups in these ethers is commonly given by a number designation after the PPG or PBG. For example, PPG-14 butyl ether, would designate a polypropylene glycol ether of butanol wherein the molecule has on average 14 propylene glycol units.
  • Nonlimiting examples of alkoxylated alcohols useful herein include PPG-10 butyl ether, PPG-11 butyl ether, PPG-12 butyl ether, PPG-13 butyl ether, PPG-14 butyl ether, PPG-15 butyl ether, PPG-16 butyl ether, PPG-17 butyl ether, PPG-18 butyl ether, PPG-19 butyl ether, PPG-20 butyl ether, PPG-22 butyl ether, PPG-24 butyl ether, PPG-30 butyl ether, PPG-11 stearyl ether, PPG-15 stearyl ether, PPG-10 oleyl ether, PPG-7 lauryl ether, PPG-30 isocetyl ether, PPG-10 glyceryl ether, PPG-15 glyceryl ether, PPG- 10 butyleneglycol ether, PPG-15 butylene glycol ether, PPG-27 glyceryl ether, PPG-30 cety
  • Preferred alkoxylated alcohols are those selected from the group consisting of PPG-14 butyl ether, PPG-15 stearyl ether, PPG-11 stearyl ether, PPG-20 oleyl ether, and mixtures thereof.
  • More preferred alkoxylated alcohols are those selected from the group consisting of PPG-14 butyl ether, PPG-15 stearyl ether, and mixtures thereof.
  • PPG-14 butyl ether is available under the tradename Fluid AP from Union Carbide Corporation.
  • PPG 15 stearyl ether is available under the tradename Arlamol E from ICI Americas Corporation.
  • Nonlimiting examples of alkoxylated polyols useful herein include those selected from the group consisting of PPG-10 1,4-butanediol, PPG-12 1 ,4-butanediol, PPG-14 1 ,4-butanediol, PPG-2 butanediol, PPG-10 1,6- hexanediol, PPG-12 1,6-hexanediol, PPG-14 hexanediol, PPG-20 hexanediol, and mixtures thereof.
  • Preferred are those selected from the group consisting of PPG-10 1 ,4-butanediol, PPG-12 1 ,4-butanediol, PPG-10 1 ,6-hexandiol, and PPG-12 hexanediol, and mixtures thereof. More preferred is PPG-10 1,4-butanediol. This compound is commercially available under the tradename Macol 57 from PPG/Mazer Corporation.
  • Polypropylene glycols and propylene glycol are useful herein, at a level of from about 1 % to about 5% by weight of the composition, preferably from about 2% to about 3.5% by weight of the composition, to enhance the penetration of the acidic active ingredient of the present invention.
  • Polypropylene glycols are polymers which are typically formed from the polymerization of propylene oxide, propylene glycol, propylchlorohydrin, propylbromohydrin, and other related materials. Polypropylene glycols are represented by the following formula:
  • n is an integer from about 10 to about 50, preferably from about 15 to about 40, and more preferably from about 20 to about 34.
  • the polypropylene glycols are commonly designated as PPG's followed by a number indicating the average number of repeating units in the structure. For example, PPG-30 would correspond to the above structure wherein n has an average value of about 30. Based on this nomenclature, the polypropylene glycols useful herein encompass those designated as PPG- 10 through PPG-50, more preferably those designated as PPG-15 through PPG-40, and most preferably those designated as PPG-20 through PPG-34.
  • Humectants Another optional component of the compositions of the present invention is a humectant.
  • the humectant can comprise from about 0.1% to about 20%, more preferably from about 0.5% to about 10%, and most preferably from about 1% to about 5% by weight of the composition. Even though these materials are defined herein as humectants, they can also possess moisturizing, skin conditioning, and other related properties.
  • humectants useful herein include materials such as urea; guanidine; saturated or unsaturated alkyl alpha hydroxy acids such as glycolic acid and glycolate salts (e.g. ammonium and quaternary alkyl ammonium) and lactic acid and lactate salts (e.g. ammonium and quaternary alkyl ammonium); aloe vera in any of its variety of forms (e.g.
  • aloe vera gel polyhydroxy alcohols such as sorbitol, glycerol, low molecular weight polypropylene glycols (e.g., dipropylene glycol and tripropylene glycol), hexanetriol, propylene glycol, butylene glycol, hexylene glycol, and the like; polyethylene glycol; sugars and starches; sugar and starch derivatives (e.g., alkoxylated glucose); hyaluronic acid; chitin, starch- grafted sodium polyacrylates such as Sanwet (RTM) IM-1000, IM-1500, and IM-2500 (available from Celanese Superabsorbent Materials, Portsmouth, VA); lactamide monoethanolamine; acetamide monoethanolamine; propoxylated glycerol (as described in U.S. Patent No. 4,976,953 to Orr et al., issued December 11,1990, which is incorporated by reference herein in its entirety); and mixtures thereof.
  • Preferred humectants useful in the compositions of the present invention are urea, C3-C6 diols and triols, low molecular weight polypropylene glycols, and propoxylated glycerin.
  • Preferred humectants include those materials selected from the group consisting of urea, propylene glycol, 1,3-dihydroxypropane, glycerin, butylene glycol, hexylene glycol, 1 ,4-dihydroxyhexane, 1,2,6-hexanetriol, dipropylene glycol, tripropylene glycol, and mixtures thereof.
  • urea glycerin
  • propylene glycol hexylene glycol
  • glycerin dipropylene glycol
  • tripropylene glycol and mixtures thereof.
  • propylene glycol urea, glycerin, and mixtures thereof.
  • Emollients can also include an emollient.
  • suitable emollients include, but are not limited to, volatile and non-volatile silicone oils (e.g., dimethicone, cyclomethicone, dimethiconol, and the like), highly branched hydrocarbons, and mixtures thereof.
  • Emollients useful in the instant invention are further described in U.S. Patent No. 4,919,934, to Deckner et al., issued April 24 1990, which is incorporated herein by reference in its entirety.
  • the emollients can typically comprise in total from about 0.1% to about 25%, more preferably from about 0.5% to about 10%, and most preferably from about 0.5% to about 5% by weight of the composition. Additional Ingredients
  • additional ingredients can be incorporated into the compositions of the present invention. These additional ingredients, at a minimum, must be acid stable.
  • additional ingredients include vitamins and derivatives thereof (e.g. tocopherol, panthenol, and the like); other thickening agents (e.g., polyacrylamide and C13-14 isoparaffin and laureth-7, available as Sepigel 305 from Seppic Corp., Fairfield, NJ; and branched polysaccharides such as scleroglucan available under the tradename Ciearogel® CS 11 from Michel Mercier Products Inc., Mountainside, NJ); saturated and/or unsaturated alkyl alpha hydroxy acids; resins; gums (e.g.
  • guar gum, xanthan gum and the like waxes (both naturally occurring and synthetic); polymers for aiding the film- forming properties and substantivity of the composition (such as a copolymer of eicosene and vinyl pyrrolidone, an example of which is available from GAF Chemical Corporation as Ganex V-220®); abrasive scrub particles for cleansing and exfoliating the skin [e.g., ACuscrub® Mild Abrasives (e.g., ACuscrub® 30, 31, 32, 40, 41, 42, 43, 44, 50, 51, and 52) available from Allied Signal, Inc., Morristown, NJ; and 3M Brand PMU Capsules microecapsulated mineral oil available from 3M Corporation, St.
  • ACuscrub® Mild Abrasives e.g., ACuscrub® 30, 31, 32, 40, 41, 42, 43, 44, 50, 51, and 52
  • ethyl panthenol aloe vera, pantothenic acid and its derivatives, clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate, allantoin, bisabalol, dipotassium glycyrrhizinate and the like.
  • Preferred ingredients are saturated and/or unsaturated alkyl alpha hydroxy acids, at a level of from about 0.05% to about 5% by weight of the composition, such as lactic acid, lactate salts (e.g. ammonium and quaternary alkyl ammonium), glycolic acid, glycolate salts (e.g.
  • alpha hydroxy acids are disclosed in Walter P. Smith, Hydroxy Acids and Skin Aging, Soap/Cosmetics/Chemical Specialties, pp. 54-59, (Sept. 1993), which is herein incorporated by reference in its entirety.
  • the present invention also relates to methods wherein an effective amount of the active ingredient is deposited on the skin in order to modify the condition being treated or to deliver the desired benefit.
  • An effective amount is an adequate amount to deliver the desired benefit but low enough to avoid serious side effects at a reasonable benefit to risk ratio within the scope of sound medical judgement.
  • What is a safe and effective amount of the acidic active will vary with the specific active, the ability of the active to penetrate through the skin, the age of the user, the health condition of the user, the skin condition of the user, and other like factors.
  • Such methods comprise topically applying to the skin or scalp, an effective amount of the composition of the present invention.
  • the composition can be applied for several days in a row, weeks, months or years at an appropriate interval.
  • Appropriate intervals are from about three times daily to about one time every three days, preferably from about two times daily to about one time every other day, more preferably about one time daily, until satisfactory results are achieved.
  • a wide range of quantities of the compositions of the present invention can be employed to provide a benefit.
  • Quantities of the present composiitons which are typically applied to provide a benefit can range form aobut 0.1 mg/cm 2 to about 10 mg/cm 2 .
  • a particularly useful amount to use is about 2 mg/cm 2 .
  • Steareth-2 2 1.0 1.0
  • compositions are prepared as follows:
  • a water phase by heating the water to a temperature of about 180°F (82°C) and adding the distearyl dimethyl ammonium chloride, glycerin, and propylene glycol. Keep this mixture at a temperature of from about 65°C to about 75°C.
  • a separate vessel prepare the oil phase by mixing the cetyl alcohol, stearyl alcohol, steareth-2, steareth-21, the dimethicone, and the cyclomethicone and heating the mixture to a temperature of from about 65° C to about 75°C.
  • compositions are useful for application to the skin for delivering the acid active are useful for treating wrinkles, dry skin and other age-related conditions of the skin. These compositions demonstrate good stability.
  • compositions are prepared in which the salicylic acid is replaced with 0.025% retinoic acid and 0.5% N-acetyl-L-cysteine, respectively, with the water levels being adjusted accordingly.
  • Leave On Composition A leave on compositions containng N-acetyl-L-cysteine as the active ingredient is prepared by combining the following ingredients using conventional mixing techniques as described below.
  • a water phase is prepared by combining about 90% of the water, glycerin, methyl paraben, and disodium EDTA and heating to 70-75 °C.
  • an oil phase is prepared by combining the PPG-15 stearyl ether, stearyl alcohol, steareth-2, distearyl dimethyl ammonium chloride, cetyl alochol, stearth-21, behenyl alcohol, propyl paraben and heating to 70-75° C.
  • the oil phase is mixed into the water phase with stirring, and the resulting mixture is flash-cooled with stirring to 35-40 °C.
  • the remaining water, N-acetyl-L-cysteine, citric acid, and zinc oxide are combined and added to the mixture with stirring. The remaining ingredients are then added with stirring.
  • composition is useful for application to the skin for delivering the active and to treat and improve the appearance of the skin.
  • Sunscreening compositions containing zinc oxide and octyl methoxycinnamate as the active ingredient is prepared by combining the following ingredients using conventional mixing techniques as described above.

Abstract

The present invention relates to leave on, skin care compositions, comprising: (A) from about 0.001 % to about 20 % of an active ingredient, (B) from about 1 % to about 20 % of a stable, hydrophobic, structuring agent selected from the group consisting of saturated C16 to C30 fatty alcohols, saturated C16 to C30 fatty alcohols containing from about 1 to about 5 moles of ethylene oxide, saturated C16 to C30 diols, saturated C16 to C30 monoglycerol ethers, saturated C16 to C30 hydroxy fatty acids, and mixtures thereof, having a melting point of at least about 45 °C; and (C) from about 0.05 % to about 10 % of a hydrophilic surfactant selected from the group consisting of anionic surfactants, cationic surfactants, zwitterionic surfactants, and mixtures thereof; and (D) from about 25 % to about 98.949 % water. These compositions are useful for delivering a wide variety of active ingredients to the skin.

Description

STABLE TOPICAL COMPOSITIONS
TECHNICAL FIELD
The present invention relates to stable, leave-on skin care cosmetic compositions containing an active ingredient. In particular it relates to stable, cosmetic, aqueous-containing compositions having gel networks, liquid crystalline phases, or both. Without being limited by theory, it is believed that the aqueous phase of these compositions contains relatively- low levels of free water. In other words, the water is believed to be bound as part of the gel network or liquid crystals. These compositions are useful for delivering a wide variety of active ingredients to the skin. BACKGROUND OF THE INVENTION
A wide variety of active ingredients are currently known for treating various skin conditions. It is difficult to formulate many of these actives into cosmetically-elegant, oil-in-water systems because of stability, solubility, ionic strength, and other such formulation considerations. Representative of some of these active ingredients are materials such as salicylic acid, N- acetyl-L-cysteine, retinoic acid, phytic acid, and their pharmaceutically- acceptable salts.
For example, cosmetic compositions containing salicylic acid, N- acetyl-L-cysteine, and retinoic acid are known in the art. Salicylic acid and retinoic acid are keratoylic agents which are believed to help remove keratin plugs and to aid the skin's exfoliation process. These materials are also known for their anti-acne and anti-skin aging benefits. See C. Huber et al., Arch. Derm Res. 257, pp. 293-297, 1977; U.S. Patent No. 4,888,342, to Kligman, issued December 19, 1989; U.S. Patent No. 4,877,805, to Kligman, Issued October 31, 1989; PCT Application No. US-92-09739, Publication No. 0614354, to R.L Blank, published June 10, 1993; and PCT Application No. US-92-09737, Publication No. 0614353, to R.L. Blank et al., published June 10, 1993, which are all incoφorated by reference herein in their entirety. N-acetyl-L-cysteine is known for regulating wrinkles and skin atrophy (i.e. the thinning and general degradation of the dermis). See U.S. Patent No. 5,296,500, to Hillebrand, issued March 22, 1994, which is incoφorated by reference herein in its entirety.
It has been found that the compositions of the present invention are well-suited for formulating and delivering a wide variety of active ingredients to the skin. Without being limited by theory, it is believed that these compositions contain gel network structures, liquid crystal structure, or both. It is believed that these gel networks and liquid crystals tend to bind the available water in the composition, thereby rendering the water less available for contributing to the instability and decomposition of the active ingredients. It is also found that these compositions are well-suited for carrying a high electrolyte concentration, making them ideal for delivering a wide range of ionic and other highly polar materials, e.g., zinc oxide, polar solvents.
Therefore, it is an object of the present invention to provide novel compositions for delivering a wide variety of active ingredients to the skin.
It is a further object of the present invention to provide water- containing compositions having gel networks, liquid crystals or both.
It is a further object of the present invention to provide water- containing compositions which can accomodate a high electrolyte concentration.
It is a further object of the present invention to provide stable compositions.
It is still a further object of the present invention to provide compositions which have acceptable aesthetic properties.
It is still a further object of the present invention to provide methods of treatment for a wide variety of skin conditions.
SUMMARY OF THE INVENTION The present invention relates to leave on skin care compositions comprising:
(A) from about 0.001 % to about 20% of an active ingredient;
(B) from about 1 % to about 20% of a hydrophobic, structuring agent selected from the group consisting of saturated C<ιe to C30 fatty alcohols, saturated C-|6 to C30 fatty alcohols containing from about 1 to about 5 moles of ethylene oxide, saturated Cie to C30 diols, saturated C- Q to C30 monoglycerol ethers, saturated C16 t0 C30 hydroxy fatty acids, and mixtures thereof, having a melting point of at least about 45°C;
(C) from about 0.05 % to about 10% of a hydrophilic surfactant selected from the group consisting of anionic surfactants, cationic surfactants, zwitterionic surfactants, amphoteric surfactants, and mixtures thereof; and (D) from about 25% to about 98.949% water.
All percentages and ratios used herein are by weight of the total composition. All measurements made are at 25°C, unless otherwise designated. The invention hereof can comprise, consist of, or consist essentially of, the essential as well as optional ingredients and components described herein.
DETAILED DESCRIPTION OF THE INVENTION
The cosmetic compositions of the present invention are useful for moisturizing and hydrating the skin and for depositing active ingredients onto the skin. These compositions are in the form of oil-in-water emulsions whereby the oil phase and the water phase can contain, in addition to the essential components described herein, a variety of ingredients known in the art. These compositions are in the form of topical, leave-on compositions.
In particular the present invention relates to leave on skin care compositions which are oil-in-water emulsions, comprising:
(A) from about 0.001 % to about 20% of an active ingredient;
(B) from about 1 % to about 20% of a, hydrophobic, structuring agent selected from the group consisting of saturated Cie to C30 fatty alcohols, saturated C-J6 to C30 fatty alcohols containing from about 1 to about 5 moles of ethylene oxide, saturated C-iβ to C30 diols, saturated C-jβ to C30 monoglycerol ethers, saturated C-|6 to C30 hydroxy fatty acids, and mixtures thereof, having a melting point of at least about 45°C;
(C) from about 0.05 % to about 10% of a hydrophilic surfactant selected from the group consisting of anionic surfactants, cationic surfactants, zwitterionic surfactants, amphoteric surfactants, and mixtures thereof; and
(D) from about 25% to about 98.949% water.
Preferably the ratio of component (B) to component (C) is from about 20:1 to about 1:1, preferably from about 10:1 to about 1:1, more preferably from about 5:1 to about 1:1, and even more preferably about 3:1. These ratios allow for the formation of lamellar liquid crystalline phases, which contribute to the physical and chemical stability of the composition at temperatures from about -10°C to about 50°C.
The compositions of the present invention have complex rheological characteristics. These compositions have physical properties characteristic of oil-in-water emulsions, liquid crystals, and crystalline gel networks. Without being limited by theory, it is believed that these compositions have low levels of free water, such that most of the water is bound up with liquid crystals or gel networks. It is found that these compositions are useful as vehicles for compositions which are labile in aqueous solution or dispersion. It is also found that these compositions are useful for formulating actives which present a high electrolyte load for the composition, i.e. actives which are ionic or highly polar.
The nature of liquid crystals, the formation of liquid crystals, the properties and advantages of liquid crystals, and gel networks are described further in G. Dahms, "Properties of O/W Emulsions with Anisotropic Lamellar Phases," 101 Cosmetics & Toiletries 113-115, (1986); P. Loll, "Liquid Crystals in Cosmetic Emulsions," ICI Surfactants' Publication RP94-93E: and G.M. Eccleston, "Multiple-Phase Oil-ln-Water Emulsion," 41 J. Soc. Cosmet. Chem. 1-22, (January/February 1990); all of which are incorporated herein by reference in their entirety.
The oil-in-water emulsions herein have desirable aesthetic and elegant properties, such as a rich and creamy, yet non-greasy, skin feel. These emulsions can span a broad range of consistencies from thin lotions to heavy creams. These emulsions typically have viscosities ranging from about 100 cps to about 500,000 cps, preferably from about 3,000 cps to about 200,000 cps, more preferably from about 5000 cps to about 150,000 cps, and even more preferably from about 5000 cps to about 100,000 cps, as measured at a temperature of 25°C with a Brookfield Synchro-Lectric Viscometer Model D. The oil-in-water emulsion compositions can span a wide range of pH values. Even though buffers can be utilized to help maintain the pH of the emulsion compositions, these are not required components, but are merely optional ingredients.
(A) Active Ingredients
The compositions of the present invention comprise a safe and effective amount of one or more active ingredients or pharmaceutically acceptable salts thereof.
The term "safe and effective amount" as used herein, means an amount of an active ingredient high enough to modify the condition to be treated or to deliver the desired skin benefit, but low enough to avoid serious side effects, at a reasonable benefit to risk ratio within the scope of sound medical judgement. What is a safe and effective amount of the active ingredient will vary with the specific active, the ability of the active to penetrate through the skin, the age, health condition, and skin condition of the user, and other like factors.
By "pharmaceutically-acceptable salts" are meant any of the commonly-used salts that are suitable for use in contact with the tissues of humans without undue toxicity, irritation, incompatibility, instability, irritation, allergic response, and the like.
Typically, the actives of the present invention comprise from about 0.001% to about 20%, preferably from about 0.01% to about 10%, and more preferably from about 0.025% to about 5% by weight of the composition.
The actives useful herein can be categorized by their therapeutic benefit or their postulated mode of action. However, it is to be understood that the actives useful herein can in some instances provide more than one therapeutic benefit or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit the active to that particular application or applications Iisted. Also, pharmaceutically-acceptable salts of these materials are useful herein. The following actives which preferably have the above outlined solubility parameters are useful in the compositions of the present invention. Anti-Acne Actives: Examples of useful anti-acne actives include the keratolytics such as salicylic acid (o-hydroxybenzoic acid), derivatives of salicylic acid such as 5-octanoyl salicylic acid, and resorcinol; retinoids such as retinoic acid and its derivatives (e.g., cis and trans); sulfur- containing D and L amino acids and their derivatives and salts, particularly their N-acetyl derivatives, a preferred example of which is N-acetyl-L- cysteine; lipoic acid; antibiotics and antimicrobials such as benzoyl peroxide, octopirox, tetracycline, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'-trichlorobanilide, azelaic acid and its derivatives, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, ethyl acetate, clindamycin and meclocycline; sebostats such as flavonoids; and bile salts such as scymnol sulfate and its derivatives, deoxycholate, and cholate. Anti-Wrinkle and Anti-Skin Atrophy Actives: Examples of antiwrinkle and anti-skin atrophy actives include retinoic acid and its derivatives (e.g., cis and trans); salicylic acid and derivatives thereof; sulfur-containing D and L amino acids and their derivatives and salts, particularly the N-acetyl derivatives, a preferred example of which is N-acetyl L-cysteine; thiols, eg. ethane thiol; alpha-hydroxy acids, e.g. glycolic acid, and lactic acid; phytic acid, lipoic acid; lysophosphatidic acid, and skin peel agents (e.g., phenol and the like).
Non-Steroidal Anti-Inflammatory Actives (NSAIDS - Examples of NSAIDS include the following categories: propionic acid derivatives; acetic acid derivatives; fenamic acid derivatives; biphenylcarboxylic acid derivatives; and oxicams. All of these NSAIDS are fully described in the U.S. Patent 4,985,459 to Sunshine et al., issued January 15, 1991, incorporated by reference herein. Examples of useful NSAIDS include acetyl salicylic acid, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen and bucloxic acid. Also useful are the steroidal anti-inflammatory drugs including hydrocortisone and the like.
Topical Anesthetics: Examples of topical anesthetic drugs include benzocaine, lidocaine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine, phenol, and pharmaceutically acceptable salts thereof.
Artificial Tanning Agents and Accelerators: Examples of artificial tanning agents accelerators include dihydroxyacetone, tyrosine, tyrosine esters such as ethyl tyrosinate, and phospho-DOPA.
Antimicrobial and Antifungal Actives: Examples of antimicrobial and antifungal actives include β-lactam drugs, quinolone drugs, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amikacin, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'-trichlorobanilide, phenoxyethanol, phenoxy propanol, phenoxyisopropanol, doxycycline, capreomycin, chlorhexidine, chlortetracycline, oxytetracycline, clindamycin, ethambutol, hexamidine isethionate, metronidazole, pentamidine, gentamicin, kanamycin, lineomycin, methacycline, methenamine, minocycline, neomycin, netilmicin, paromomycin, streptomycin, tobramycin, miconazole, tetracycline hydrochloride, erythromycin, zinc erythromycin, erythromycin estolate, erythromycin stearate, amikacin sulfate, doxycycline hydrochloride, capreomycin sulfate, chlorhexidine gluconate, chlorhexidine hydrochloride, chlortetracycline hydrochloride, oxytetracycline hydrochloride, clindamycin hydrochloride, ethambutol hydrochloride, metronidazole hydrochloride, pentamidine hydrochloride, gentamicin sulfate, kanamycin sulfate, lineomycin hydrochloride, methacycline hydrochloride, methenamine hippurate, methenamine mandelate, minocycline hydrochloride, neomycin sulfate, netilmicin sulfate, paromomycin sulfate, streptomycin sulfate, tobramycin sulfate, miconazole hydrochloride, amanfadine hydrochloride, amanfadine sulfate, octopirox, parachlorometa xylenol, nystatin, tolnaftate and clotrimazole.
Sunscreening Actives: Also useful herein are sunscreening agents. A wide variety of sunscreening agents are described in U.S. Patent No. 5,087,445, to Haffey et al., issued February 11, 1992; U.S. Patent No. 5,073,372, to Turner et al., issued December 17, 1991; U.S. Patent No. 5,073,371, to Turner et al. issued December 17, 1991; and Segarin, et al., at Chapter VIII, pages 189 et seq., of Cosmetics Science and Technology, all of which are incorporated herein by reference in their entirety. Preferred among those sunscreens which are useful in the compositions of the instant invention are those selected from the group consisting of 2-ethylhexyl p- methoxycinnamate, octyl methoxycinnamate, l-p-aminobenzoate, p- aminobenzoic acid, 2-phenylbenzimidazole-5-sulfonic acid, octocrylene, oxybenzone, homomenthyl salicylate, octyl salicylate, 4,4'-methoxy-t- butyldibenzoylmethane, 4-isopropyl dibenzoylmethane, 3-benzylidene camphor, 3-(4-methylbenzylidene) camphor, titanium dioxide, zinc oxide, silica, iron oxide, and mixtures thereof. Still other useful sunscreens are those disclosed in U.S. Patent No. 4,937,370, to Sabatelli, issued June 26, 1990; and U.S. Patent No. 4,999,186, to Sabatelli et al., issued March 12, 1991; these two references are incorporated by reference herein in their entirety. The sunscreening agents disclosed therein have, in a single molecule, two distinct chromophore moieties which exhibit different ultra¬ violet radiation absoφtion spectra. One of the chromophore moieties absorbs predominantly in the UVB radiation range and the other absorbs strongly in the UVA radiation range. These sunscreening agents provide higher efficacy, broader UV absorption, Iower skin penetration and longer lasting efficacy relative to conventional sunscreens. Especially preferred examples of these sunscreens include those selected from the group consisting of 4-N,N-(2-ethylhexyl)methylaminobenzoic acid ester of 2,4- dihydroxybenzophenone, 4-N,N-(2-ethylhexyl)methylaminobenzoic acid ester with 4-hydroxydibenzoylmethane, 4-N.N- (2-ethylhexyl)methylamino- benzoic acid ester of 2-hydroxy-4-(2-hydroxyethoxy)benzophenone, 4-N.N- (2-ethylhexyl)-methylaminobenzoic acid ester of 4-(2-hydroxyeth- oxy)dibenzoylmethane, and mixtures thereof. Generally, the sunscreens can comprise from about 0.5% to about 20% of the compositions useful herein. Exact amounts will vary depending upon the sunscreen chosen and the desired Sun Protection Factor (SPF). SPF is a commonly used measure of photoprotection of a sunscreen against erythema. See Federal Register. Vol. 43, No. 166, pp. 38206-38269, August 25, 1978, which is incorporated herein by reference in its entirety.
Preferred examples of actives useful herein include those selected from the group consisting of salicylic acid, 3-hydroxy benzoic acid, 4- hydroxy benzoic acid, acetyl salicylic acid, 2-hydroxybutanoic acid, 2- hydroxypentanoic acid, 2-hydroxyhexanoic acid, cis-retinoic acid, trans- retinoic acid, N-acetyl L-cysteine, lipoic acid, azelaic acid, arachidonic acid, benzoylperoxide, tetracycline, ibuprofen, naproxen, hydrocortisone, acetominophen, resorcinol, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'- trichlorocarbanilide, octopirox, lidocaine hydrochloride, clotrimazole, miconazole, neocycin sulfate, p-aminobenzoic acid, 2-phenylbenzimidazole- 5-sulfonic acid, dihydroxyacetone, and mixtures thereof.
More preferred examples of actives useful herein include those selected from the group consisting of salicylic acid, acetyl salicylic acid, cis- retinoic acid, trans-retinoic acid, N-acetyl-L-cysteine, lipoic acid, azelaic acid, tetracycline, ibuprofen, naproxen, acetominophen, hydrocortisone, resorcinol, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4'- trichloro- -hydroxy diphenyl ether, 3,4,4'-trichlorocarbanilide, octopirox, 2- phenylbenzimidazole-5-sulfonic acid, dihydroxyacetone, and mixtures thereof.
Most preferred examples of actives useful herein include those selected from the group consisting of salicylic acid, cis-retinoic acid, trans- retinoic acid, N-acetyl L-cysteine, azelaic acid, lipoic acid, resorcinol, ibuprofen, naproxen, hydrocortisone, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'- trichlorocarbanilide, 2-phenylbenzimidazole-5-sulfonic acid, dihydroxyacetone, and mixtures thereof.
(B) Structuring Agent
The present invention also comprises from about 1% to about 20%, preferably from about 1% to about 10%, more preferably from about 3% to about 9%, of a stable, hydrophobic, structuring agent selected from the group consisting of saturated C-|6 to C30 fatty alcohols, saturated C-|6 to C30 fatty alcohols containing from about 1 to about 5 moles of ethylene oxide, saturated C-jβ to C30 diols, saturated C-J6 to C30 monoglycerol ethers, saturated C-|6 to C30 hydroxy fatty acids, and mixtures thereof, having a melting point of at least about 45°C. Without being limited by theory, it is believed that these structuring agents are useful to assist in the formation of the rheological characteristic of the composition which contribute to the hydrolytic stability of the composition of the present invention. In particular structuring agents assist in the formation of the liquid crystalline gel network structures.
The preferred structuring agents of the present invention are selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmitic acid, the polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 5 ethylene oxide units, the polyethylene glycol ether of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof. More preferred structuring agents of the present invention are selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol, the polyethylene glycol ether of stearyl alcohol having an average of about 2 ethylene oxide units (steareth-2), the polyethylene glycol ether of cetyl alcohol having an average of about 2 ethylene oxide units, and mixtures thereof. Even more preferred structuring agents are selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol, steareth- 2, and mixtures thereof. Most preferred is steareth-2, available under the tradename of Brij® 72 from ICI Americas.
(C) Hvdrophilic Surfactant
The compositions of the present invention comprise from about 0.05% to about 10%, preferably from about 1% to about 6%, and more preferably from about 1 % to about 3% of at least one hydrophilic surfactant which can disperse the hydrophobic materials in the water phase. The surfactant, at a minimum, must be hydrophilic enough to disperse in water.
The surfactants useful herein can include any of a wide variety of cationic, anionic, zwitterionic, and amphoteric surfactants disclosed in prior patents and other references. See McCutcheon's, Detergents and Emulsifiers. North American Edition (1986), published by Allured Publishing Coφoration; U.S. Patent No. 5,011,681 to Ciotti et al., issued April 30, 1991; U.S. Patent No. 4,421,769 to Dixon et al., issued December 20, 1983; and U.S. Patent No. 3,755,560 to Dickert et al., issued August 28, 1973; these four references are incorporated herein by reference in their entirety.
The exact surfactant chosen will depend upon the pH of the composition and the other components present.
Preferred herein are cationic surfactants, especially dialkyi quaternary ammonium compounds. A wide variety of cationic surfactants useful herein are disclosed in U.S. Patent No. 5,151,209, to McCall et al., issued September 29, 1992; U.S. Patent No. 5,151,210, to Steuri et al., issued September 29, 1992; U.S. Patent No. 5,120,532, to Wells et al., issued June 9, 1992; U.S. Patent No. 4,387,090, to Bolich, issued June 7, 1983;; U.S. Patent 3,155,591, Hilfer, issued November 3, 1964; U.S. Patent No. 3,929,678, to Laughlin et al., issueo December 30, 1975; U.S. Patent No. 3,959,461, to Bailey et al., issued May 25, 1976; McCutcheon's. Detergents & Emulsifiers. (North American edition 1979) M.C. Publishing Co.; and Schwartz, et al., Surface Active Agents. Their Chemistry and Technology. New York: Interscience Publishers, 1949; all of these documents being incoφorated herein by reference in their entirety. The cationic surfactants useful herein include cationic ammonium salts such as those having the formula:
Figure imgf000012_0001
wherein R-j, is an alkyl group having from about 12 to about 30 carbon atoms, or an aromatic, aryl or alkaryl groups having from about 12 to about 30 carbon atoms; R2, R3, and R4 are independently selected from hydrogen, an alkyl group having from about 1 to about 22 carbon atoms, or aromatic, aryl or alkaryl groups having from about 12 to about 22 carbon atoms; and X is any compatible anion, preferably selected from the group consisting of chloride, bromide, iodide, acetate, phosphate, nitrate, sulfate, methyl sulfate, ethyl sulfate, tosylate, lactate, citrate, glycolate, and mixtures thereof. Additionally, the alkyl groups of R-j, R2, R3, and R can also contain ester and/or ether linkages, or hydroxy or amino group substituents (e.g., the alkyl groups can contain polyethylene glycol and polypropylene glycol moieties). More preferably, R-j is an alkyl group having from about 12 to about 22 carbon atoms; R2 is selected from H or an alkyl group having from about 1 to about 22 carbon atoms; R3 and R4 are independently selected from H or an alkyl group having from about 1 to about 3 carbon atoms; and X is as described previously.
Most preferably, R-j is an alkyl group having from about 12 to about 22 carbon atoms; R2, R3. and R4 are selected from H or an alkyl group having from about 1 to about 3 carbon atoms; and X is as described previously.
Alternatively, other useful cationic emulsifiers include amino-amides, wherein in the above structure R<j is alternatively R5CONH-(CH2)rr. wherein R5 is an alkyl group having from about 12 to about 22 carbon atoms, and n is an integer from about 2 to about 6, more preferably from about 2 to about 4, and most preferably from about 2 to about 3. Nonlimiting examples of these cationic emulsifiers include stearamidopropyl PG-dimonium chloride phosphate, behenamidopropyl PG dimonium chloride, stearamidopropyl ethyldimonium ethosulfate, stearamidopropyl dimethyl (myristyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosylate, stearamidopropyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate, and mixtures thereof. Especially preferred is behenamidopropyl PG dimonium chloride.
Nonlimiting examples of quatemary ammonium salt cationic surfactants include those selected from the group consisting of cetyl ammonium chloride, cetyl ammonium bromide, lauryl ammonium chloride, lauryl ammonium bromide, stearyl ammonium chloride, stearyl ammonium bromide, cetyl dimethyl ammonium chloride, cetyl dimethyl ammonium bromide, lauryl dimethyl ammonium chloride, lauryl dimethyl ammonium bromide, stearyl dimethyl ammonium chloride, stearyl dimethyl ammonium bromide, cetyl trimethyl ammonium chloride, cetyl trimethyl ammonium bromide, lauryl trimethyl ammonium chloride, lauryl trimethyl ammonium bromide, stearyl trimethyl ammonium chloride, stearyl trimethyl ammonium bromide, lauryl dimethyl ammonium chloride, stearyl dimethyl cetyl ditallow dimethyl ammonium chloride, dicetyl ammonium chloride, dicetyl ammonium bromide, dilauryl ammonium chloride, dilauryl ammonium bromide, distearyl ammonium chloride, distearyl ammonium bromide, dicetyl methyl ammonium chloride, dicetyl methyl ammonium bromide, dilauryl methyl ammonium chloride, dilauryl methyl ammonium bromide, distearyl methyl ammonium chloride, distearyl methyl ammonium bromide, and mixtures thereof. Additional quaternary ammonium salts include those wherein the C-J2 to C30 alkyl carbon chain is derived from a tallow fatty acid or from a coconut fatty acid. The term "tallow" refers to an alkyl group derived from tallow fatty acids (usually hydrogenated tallow fatty acids), which generally have mixtures of alkyl chains in the C-jg to C-jβ range. The term "coconut" refers to an alkyl group derived from a coconut fatty acid, which generally have mixtures of alkyl chains in the C<| 2 to C 1 range. Examples of quaternary ammonium salts derived from these tallow and coconut sources include ditallow dimethyl ammonium chloride, ditallow dimethyl ammonium methyl sulfate, di(hydrogenated tallow) dimethyl ammonium chloride, di(hydrogenated tallow) dimethyl ammonium acetate, ditallow dipropyl ammonium phosphate, ditallow dimethyl ammonium nitrate, di(coconutalkyl)dimethyl ammonium chloride, di(coconutalkyl)dimethyl ammonium bromide, tallow ammonium chloride, coconut ammonium chloride, stearamidopropyl PG-dimonium chloride phosphate, stearamidopropyl ethyldimonium ethosulfate, stearamidopropyl dimethyl (myristyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosylate, stearamidopropyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate, and mixtures thereof. An example of a quaternary ammonium compound having an alkyl group with an ester linkage is ditallowyl oxyethyl dimethyl ammonium chloride.
More preferred cationic surfactants are those selected from the group consisting of behenamidopropyl PG dimonium chloride, dilauryl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, dimyristyl dimethyl ammonium chloride, dipalmityl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, stearamidopropyl PG-dimonium chloride phosphate, stearamidopropyl ethyldiammonium ethosulfate, stearamidopropyl dimethyl (myristyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosylate, stearamidopropyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate, and mixtures thereof.
Most preferred cationic surfactants are those selected from the group consisting of behenamidopropyl PG dimonium chloride, dilauryl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, dimyristyl dimethyl ammonium chloride, dipalmityl dimethyl ammonium chloride, and mixtures thereof. A preferred combination of cationic surfactant and structuring agent is behenamidopropyl PG dimonium chloride and/or behenyl alcohol, wherein the ratio is preferably optimized to maintained to enhance physical and chemical stability, especially when such a combination contains ionic and/or highly polar solvents. This combination is especially useful for delivery of sunscreening agents such as zinc oxide and octyl methoxycinnamate.
A wide variety of anionic surfactants are also useful herein. See, e.g., U.S. Patent No. 3,929,678, to Laughlin et al., issued December 30, 1975, which is incorporated herein by reference in its entirety. Nonlimiting examples of anionic surfactants include the alkoyl isethionates, and the alkyl and alkyl ether sulfates. The alkoyl isethionates typically have the formula RCO-OCH2CH2SO3M wherein R is alkyl or alkenyl of from about 10 to about 30 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium and triethanolamine. Nonlimiting examples of these isethionates include those alkoyl isethionates selected from the group consisting of ammonium cocoyl isethionate, sodium cocoyl isethionate, sodium lauroyl isethionate, sodium stearoyl isethionate, and mixtures thereof.
The alkyl and alkyl ether sulfates typically have the respective formulae ROSO3M and RO(C2H4O)χSO3M, wherein R is alkyl or alkenyl of from about 10 to about 30 carbon atoms, x is from about 1 to about 10, and M is a water-soluble cation such as ammonium, sodium, potassium and triethanolamine. Another suitable class of anionic surfactants are the water-soluble salts of the organic, sulfuric acid reaction products of the general formula:
R^SOg-M wherein R1 is chosen from the group consisting of a straight or branched chain, saturated aliphatic hydrocarbon radical having from about 8 to about 24, preferably about 10 to about 16, carbon atoms; and M is a cation. Still other anionic synthetic surfactants include the class designated as succinamates, olefin sulfonates having about 12 to about 24 carbon atoms, and b-alkyloxy alkane sulfonates. Examples of these materials are sodium lauryl sulfate and ammonium lauryl sulfate.
Other anionic materials useful herein are soaps (i.e. alkali metal salts, e.g., sodium or potassium salts) of fatty acids, typically having from about 8 to about 24 carbon atoms, preferably from about 10 to about 20 carbon atoms. The fatty acids used in making the soaps can be obtained from natural sources such as, for instance, plant or animal-derived glycerides (e.g., palm oil, coconut oil, soybean oil, castor oil, tallow, lard, etc.) The fatty acids can also be synthetically prepared. Soaps are described in more detail in U.S. Patent No. 4,557,853, cited above.
Amphoteric and zwitterionic surfactants are also useful herein. Examples of amphoteric and zwitterionic surfactants which can be used in the compositions of the present invention are those which are broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical can be straight or branched chain and wherein one of the aliphatic substituents contains from about 8 to about 22 carbon atoms (preferably Cβ - C-jβ) and one contains an anionic water solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate. Examples are alkyl imino acetates, and iminodialkanoates and aminoalkanoates of the formulas RN[CH2)mCO2M]2 and RNH(CH2)mCO2M wherein m is from 1 to 4, R is a C8-C22 alkyl or alkenyl, and M is H, alkali metal, alkaline earth metal ammonium, or alkanolammonium. Also included are imidazolinium and ammonium derivatives. Specific examples of suitable amphoteric surfactants include sodium 3-dodecyl-aminopropionate, sodium 3-dodecylaminoproρane sulfonate, N-alkyltaurines such as the one prepared by reacting dodecylamine with sodium isethionate according to the teaching of U.S. Patent 2,658,072 which is incoφorated herein by reference in its entirety; N-higher alkyl aspartic acids such as those produced according to the teaching of U.S. Patent 2,438,091 which is incoφorated herein by reference in its entirety; and the products sold under the trade name "Miranol" and described in U.S. Patent 2,528,378, which is incoφorated herein by reference in its entirety. Other examples of useful amphoterics include phosphates, such as coamidopropyl PG-dimonium chloride phosphate (commercially available as Monaquat PTC, from Mona Coφ.).
Also useful herein as amphoteric or zwitterionic surfactants are the betaines. Examples of betaines include the higher alkyl betaines, such as coco dimethyl carboxymethyl betaine, lauryl dimethyl carboxymethyl betaine, lauryl dimethyl alphacarboxyethyl betaine, cetyl dimethyl carboxymethyl betaine, cetyl dimethyl betaine (available as Lonzaine 16SP from Lonza Coφ.), lauryl bis-(2-hydroxyethyl) carboxymethyl betaine, stearyl bis-(2-hydroxypropyl) carboxymethyl betaine, oleyl dimethyl gamma- -carboxypropyl betaine, lauryl bis-(2-hydroxypropyl)alpha-carboxyethyl betaine, coco dimethyl sulfopropyl betaine, stearyl dimethyl sulfopropyl betaine, lauryl dimethyl sulfoethyl betaine, lauryl bis-(2-hydroxyethyl) sulfopropyl betaine, and amidobetaines and amidosulfobetaines (wherein the RCONH(CH2)3 radical is attached to the nitrogen atom of the betaine), oleyl betaine (available as amphoteric Velvetex OLB-50 from Henkel), and cocamidopropyl betaine (available as Velvetex BK-35 and BA-35 from Henkel).
Other useful amphoteric and zwitterionic surfactants include the sultaines and hydroxysultaines such as cocamidopropyl hydroxysultaine (available as Mirataine CBS from Rhone-Poulenc), and the alkanoyl sarcosinates corresponding to the formula RCON(CH3)CH2CH2CO2M wherein R is alkyl or alkenyl of about 10 to about 20 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium and trialkanolamine (e.g., triethanolamine), a preferred example of which is sodium lauroyl sarcosinate.
(D) Water
The compositions of the present invention comprise from about 25% to about 98.949%, more preferably from about 65% to about 95%, and most preferably from about 70% to about 90% water.
Optional Components
Each of the water and oil phases of the emulsions can comprise a wide variety of optional components. Typical of such optional components are:
Alkoxylated Alcohols The compositions of the present invention comprise from about 0.1% to about 25%, preferably from about 0.1% to about 15%, and more preferably from about 6% to about 10% of an alkoxylated alcohol and/or alkoxylated polyol. The alkoxylated alcohols and polyols useful herein generally are hydrophobic, having a solubility in water of less than about 1 gram per about 100 grams of water at 25°C. Preferably, these solvents have a minimum of 10-20 moles of propylene oxide. These compounds are typically formulated into the oil phase of the oil-in-water emulsions as described in the Examples below. Mixtures of alkoxylated alcohols and polyols can be used herein. The alkoxylated alcohols useful herein can be described by the following general formula:
R— O (CHCH2O)nH X wherein R is selected from the group consisting of alcohols, polyols, diols, and mixtures thereof, having a chainlength of from about 2 to about 30 carbon atoms; n is an integer from about 3 to about 40; X is selected from the group consisting of hydrogen, methyl, ethyl, propyl, and mixtures thereof.
Preferably R is selected from the group consisting of alcohols, polyols, diols, or mixtures thereof, having a chainlength of from about 4 to about 20 carbon atoms; X is methyl; and n is an integer from about 6 to about 35. More preferably R is selected from the group consisting of alcohols, polyols, diols, or mixtures thereof, having a chainlength of from about 4 to about 18 carbon atoms; X is methyl; and n is an integer from about 10 to about 20.
Nonlimiting examples of classes of alkoxylated alcohols useful herein include propoxylated and butoxylated ethers of alcohols and polyols. These compounds can be described as PPG and PBG alkyl ethers wherein the PPG and PBG are commonly used designations for polypropylene glycol and polybutylene glycol, respectively. The average number of PPG or PBG groups in these ethers is commonly given by a number designation after the PPG or PBG. For example, PPG-14 butyl ether, would designate a polypropylene glycol ether of butanol wherein the molecule has on average 14 propylene glycol units.
Nonlimiting examples of alkoxylated alcohols useful herein include PPG-10 butyl ether, PPG-11 butyl ether, PPG-12 butyl ether, PPG-13 butyl ether, PPG-14 butyl ether, PPG-15 butyl ether, PPG-16 butyl ether, PPG-17 butyl ether, PPG-18 butyl ether, PPG-19 butyl ether, PPG-20 butyl ether, PPG-22 butyl ether, PPG-24 butyl ether, PPG-30 butyl ether, PPG-11 stearyl ether, PPG-15 stearyl ether, PPG-10 oleyl ether, PPG-7 lauryl ether, PPG-30 isocetyl ether, PPG-10 glyceryl ether, PPG-15 glyceryl ether, PPG- 10 butyleneglycol ether, PPG-15 butylene glycol ether, PPG-27 glyceryl ether, PPG-30 cetyl ether, PPG-28 cetyl ether, PPG-10 cetyl ether, PPG-10 hexylene glycol ether, PPG-15 hexylene glycol ether, PPG-10 1,2,6- hexanetriol ether, PPG-15 1 ,2,6-hexanetriol ether, and mixtures thereof.
Preferred alkoxylated alcohols are those selected from the group consisting of PPG-14 butyl ether, PPG-15 stearyl ether, PPG-11 stearyl ether, PPG-20 oleyl ether, and mixtures thereof.
More preferred alkoxylated alcohols are those selected from the group consisting of PPG-14 butyl ether, PPG-15 stearyl ether, and mixtures thereof. PPG-14 butyl ether is available under the tradename Fluid AP from Union Carbide Corporation. PPG 15 stearyl ether is available under the tradename Arlamol E from ICI Americas Corporation.
Nonlimiting examples of alkoxylated polyols useful herein include those selected from the group consisting of PPG-10 1,4-butanediol, PPG-12 1 ,4-butanediol, PPG-14 1 ,4-butanediol, PPG-2 butanediol, PPG-10 1,6- hexanediol, PPG-12 1,6-hexanediol, PPG-14 hexanediol, PPG-20 hexanediol, and mixtures thereof. Preferred are those selected from the group consisting of PPG-10 1 ,4-butanediol, PPG-12 1 ,4-butanediol, PPG-10 1 ,6-hexandiol, and PPG-12 hexanediol, and mixtures thereof. More preferred is PPG-10 1,4-butanediol. This compound is commercially available under the tradename Macol 57 from PPG/Mazer Corporation. Polypropylene Glvcols Polypropylene glycols and propylene glycol are useful herein, at a level of from about 1 % to about 5% by weight of the composition, preferably from about 2% to about 3.5% by weight of the composition, to enhance the penetration of the acidic active ingredient of the present invention. Polypropylene glycols are polymers which are typically formed from the polymerization of propylene oxide, propylene glycol, propylchlorohydrin, propylbromohydrin, and other related materials. Polypropylene glycols are represented by the following formula:
H [OCH2CH] OH
CH3 wherein n is an integer from about 10 to about 50, preferably from about 15 to about 40, and more preferably from about 20 to about 34. In the above structure, even though one isomeric orientation is depicted for convenience, this depiction is not intended to preclude other isomeric structures. The polypropylene glycols are commonly designated as PPG's followed by a number indicating the average number of repeating units in the structure. For example, PPG-30 would correspond to the above structure wherein n has an average value of about 30. Based on this nomenclature, the polypropylene glycols useful herein encompass those designated as PPG- 10 through PPG-50, more preferably those designated as PPG-15 through PPG-40, and most preferably those designated as PPG-20 through PPG-34. Humectants Another optional component of the compositions of the present invention is a humectant. When used herein, the humectant can comprise from about 0.1% to about 20%, more preferably from about 0.5% to about 10%, and most preferably from about 1% to about 5% by weight of the composition. Even though these materials are defined herein as humectants, they can also possess moisturizing, skin conditioning, and other related properties.
Examples of humectants useful herein include materials such as urea; guanidine; saturated or unsaturated alkyl alpha hydroxy acids such as glycolic acid and glycolate salts (e.g. ammonium and quaternary alkyl ammonium) and lactic acid and lactate salts (e.g. ammonium and quaternary alkyl ammonium); aloe vera in any of its variety of forms (e.g. aloe vera gel); polyhydroxy alcohols such as sorbitol, glycerol, low molecular weight polypropylene glycols (e.g., dipropylene glycol and tripropylene glycol), hexanetriol, propylene glycol, butylene glycol, hexylene glycol, and the like; polyethylene glycol; sugars and starches; sugar and starch derivatives (e.g., alkoxylated glucose); hyaluronic acid; chitin, starch- grafted sodium polyacrylates such as Sanwet (RTM) IM-1000, IM-1500, and IM-2500 (available from Celanese Superabsorbent Materials, Portsmouth, VA); lactamide monoethanolamine; acetamide monoethanolamine; propoxylated glycerol (as described in U.S. Patent No. 4,976,953 to Orr et al., issued December 11,1990, which is incorporated by reference herein in its entirety); and mixtures thereof.
Preferred humectants useful in the compositions of the present invention are urea, C3-C6 diols and triols, low molecular weight polypropylene glycols, and propoxylated glycerin. Preferred humectants include those materials selected from the group consisting of urea, propylene glycol, 1,3-dihydroxypropane, glycerin, butylene glycol, hexylene glycol, 1 ,4-dihydroxyhexane, 1,2,6-hexanetriol, dipropylene glycol, tripropylene glycol, and mixtures thereof. More preferred are those selected from the group consisting of urea, glycerin, propylene glycol, hexylene glycol, glycerin, dipropylene glycol, tripropylene glycol, and mixtures thereof. Most preferred is propylene glycol, urea, glycerin, and mixtures thereof.
Emollients The compositions of the present invention can also include an emollient. Examples of suitable emollients include, but are not limited to, volatile and non-volatile silicone oils (e.g., dimethicone, cyclomethicone, dimethiconol, and the like), highly branched hydrocarbons, and mixtures thereof. Emollients useful in the instant invention are further described in U.S. Patent No. 4,919,934, to Deckner et al., issued April 24 1990, which is incorporated herein by reference in its entirety.
The emollients can typically comprise in total from about 0.1% to about 25%, more preferably from about 0.5% to about 10%, and most preferably from about 0.5% to about 5% by weight of the composition. Additional Ingredients
A variety of additional ingredients can be incorporated into the compositions of the present invention. These additional ingredients, at a minimum, must be acid stable. Non-limiting examples of these additional ingredients include vitamins and derivatives thereof (e.g. tocopherol, panthenol, and the like); other thickening agents (e.g., polyacrylamide and C13-14 isoparaffin and laureth-7, available as Sepigel 305 from Seppic Corp., Fairfield, NJ; and branched polysaccharides such as scleroglucan available under the tradename Ciearogel® CS 11 from Michel Mercier Products Inc., Mountainside, NJ); saturated and/or unsaturated alkyl alpha hydroxy acids; resins; gums (e.g. guar gum, xanthan gum and the like); waxes (both naturally occurring and synthetic); polymers for aiding the film- forming properties and substantivity of the composition (such as a copolymer of eicosene and vinyl pyrrolidone, an example of which is available from GAF Chemical Corporation as Ganex V-220®); abrasive scrub particles for cleansing and exfoliating the skin [e.g., ACuscrub® Mild Abrasives (e.g., ACuscrub® 30, 31, 32, 40, 41, 42, 43, 44, 50, 51, and 52) available from Allied Signal, Inc., Morristown, NJ; and 3M Brand PMU Capsules microecapsulated mineral oil available from 3M Corporation, St. Paul, MN]; preservatives for maintaining the antimicrobial integrity of the compositions; skin penetration aids such as DMSO, 1- dodecylazacycloheptan-2-one (available as Azone® from the Upjohn Co.) and the like; skin bleaching (or lightening) agents including but not limited to hydroquinone, kojic acid and sodium metabisulfite; chelators and sequestrants; and aesthetic components such as fragrances, pigments, colorings, essential oils, skin sensates, astringents, skin soothing agents, skin healing agents and the like, nonlimiting examples of these aesthetic components include panthenol and derivatives (e.g. ethyl panthenol), aloe vera, pantothenic acid and its derivatives, clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate, allantoin, bisabalol, dipotassium glycyrrhizinate and the like. Preferred ingredients are saturated and/or unsaturated alkyl alpha hydroxy acids, at a level of from about 0.05% to about 5% by weight of the composition, such as lactic acid, lactate salts (e.g. ammonium and quaternary alkyl ammonium), glycolic acid, glycolate salts (e.g. ammonium and quaternary alkyl ammonium), and fruit acids. A discussion of alpha hydroxy acids is disclosed in Walter P. Smith, Hydroxy Acids and Skin Aging, Soap/Cosmetics/Chemical Specialties, pp. 54-59, (Sept. 1993), which is herein incorporated by reference in its entirety.
Methods of Treatment
The present invention also relates to methods wherein an effective amount of the active ingredient is deposited on the skin in order to modify the condition being treated or to deliver the desired benefit. An effective amount is an adequate amount to deliver the desired benefit but low enough to avoid serious side effects at a reasonable benefit to risk ratio within the scope of sound medical judgement. What is a safe and effective amount of the acidic active will vary with the specific active, the ability of the active to penetrate through the skin, the age of the user, the health condition of the user, the skin condition of the user, and other like factors. Such methods comprise topically applying to the skin or scalp, an effective amount of the composition of the present invention. The composition can be applied for several days in a row, weeks, months or years at an appropriate interval. Appropriate intervals are from about three times daily to about one time every three days, preferably from about two times daily to about one time every other day, more preferably about one time daily, until satisfactory results are achieved. A wide range of quantities of the compositions of the present invention can be employed to provide a benefit. Quantities of the present composiitons which are typically applied to provide a benefit can range form aobut 0.1 mg/cm2 to about 10 mg/cm2. A particularly useful amount to use is about 2 mg/cm2.
EXAMPLES
The following examples further describe and demonstrate embodiments within the scope of the present invention. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention, as many variations thereof are possible without departing from the spirit and scope of the invention.
Ingredients are identified by chemical or CTFA name. EXAMPLES Ml Leave On Moisturizing Compositions Leave on moisturizing, oil-in-water emulsions are prepared by combining the following ingredients using conventional mixing techniques as described below.
Ingredient I II
WT.% WT.%
Salicylic Acid 2 1.5
PPG-14 Butyl Ether 8.00 8.00
Glycerin 4.00 4.00
Stearyl Alcohol 1.5 1.5
Cetyl Alcohol 3.00 3.00
Distearyl Dimethyl 0.1 0.1 Ammonium Chloride
Propylene Glycol 3.00 3.00
Steareth-211 2.0 2.0
Steareth-22 1.0 1.0
Dimethicone3 1.0 1.0
Cyclomethicone4 1.0 1.0
Disodium EDTA 0.02 0.02
Minors 0.07 0.07
Water QS 100 QS 100
'•Polyethylene glycol ether of stearyl alcohol with an average of about 21 moles of ethylene oxide.
2Polyethyiene glycol ether of stearyl alcohol with an average of about 2 moles of ethylene oxide.
3A mixture of fully methylated linear siloxane polymers end blocked with trimethyldiloxy units.
4A cyclic dimethyl polysiioxane compound.
The above compositions are prepared as follows:
First prepare a water phase by heating the water to a temperature of about 180°F (82°C) and adding the distearyl dimethyl ammonium chloride, glycerin, and propylene glycol. Keep this mixture at a temperature of from about 65°C to about 75°C. In a separate vessel prepare the oil phase by mixing the cetyl alcohol, stearyl alcohol, steareth-2, steareth-21, the dimethicone, and the cyclomethicone and heating the mixture to a temperature of from about 65° C to about 75°C.
In a separate vessel prepare the salicylic acid phase by mixing the salicylic acid into the PPG-14 butyl ether at a temperature of from about 65° C to about 75°C.
Thereafter, mix the salicylic acid phase into the oil phase at a temperature of from about 65°C to about 75°C. Add the oil phase mixture to the water phase mixture and mill at a temperature of from about 65°C to about 75°C. Cool the resulting mixt re to a temperature of from about 40°C to about 50°C. Thereafter, add a mixture comprising the minor ingredients and the disodium EDTA to the emulsion. Cool to ambient temperature. In the altemative the above compositions can be prepared as follows:
First prepare a water phase by heating the water to a temperature of about 180°F (82°C) and adding the distearyl dimethyl ammonium chloride, glycerin, propylene glycol, cetyl alcohol, stearyl alcohol, steareth-2, and steareth-21. Keep this mixture at a temperature of from about 65°C to about 75°C.
In a separate vessel prepare the salicylic acid phase by mixing the salicylic acid, PPG-14 butyl ether, the dimethicone, and the cyclomethicone at a temperature of from about 65°C to about 75°C.
Thereafter, mix the salicylic acid phase mixture into the water phase mixture and mill at a temperature of from about 65°C to about 75°C. Cool the resulting mixture to a temperature of from about 40°C to about 50°C. Thereafter, add a mixture comprising the minor ingredients and the disodium EDTA to the emulsion. Cool to ambient temperature.
The resulting compositions are useful for application to the skin for delivering the acid active are useful for treating wrinkles, dry skin and other age-related conditions of the skin. These compositions demonstrate good stability.
In further embodiments compositions are prepared in which the salicylic acid is replaced with 0.025% retinoic acid and 0.5% N-acetyl-L-cysteine, respectively, with the water levels being adjusted accordingly. EXAMPLE III
Leave On Composition A leave on compositions containng N-acetyl-L-cysteine as the active ingredient is prepared by combining the following ingredients using conventional mixing techniques as described below.
Ingredient Weight %
Water QS 100
PPG-15 Stearyl Ether 3.25
Glycerin 3.0
Stearyl Alcohol 2.028
Steareth-2 1.097
Polyethylene1 1.0
Dimethicone2 1.0
Distearyl Dimethyl Ammonium Chloride 0.95
Cyclomethicone (and) Dimethiconol3 0.75
Sodium Hydroxide 0.58
Cetyl Alcohol 0.559
N-Acetyl-L-Cysteine 0.50
Benzyl Alcohol 0.50
Steareth-21 0.366
Methyl Paraben 0.25
Behenyl Alcohol 0.221
Fragrance 0.20
Citric Acid 0.19
Disodium EDTA 0.13
Propyl Paraben 0.10
Zinc Oxide 0.025
1 Low density polyethylene powder available from U.S. Industrial Chemical as MN-714 and MN-722.
2 Available as Dow Corning 10 Centistoke dimethicone fluid from Dow Corning Corporation.
3 Available as Dow Coming Q2-1401 fluid from Dow Corning Corporation. The above composition is prepared as follows:
A water phase is prepared by combining about 90% of the water, glycerin, methyl paraben, and disodium EDTA and heating to 70-75 °C. Next, an oil phase is prepared by combining the PPG-15 stearyl ether, stearyl alcohol, steareth-2, distearyl dimethyl ammonium chloride, cetyl alochol, stearth-21, behenyl alcohol, propyl paraben and heating to 70-75° C. The oil phase is mixed into the water phase with stirring, and the resulting mixture is flash-cooled with stirring to 35-40 °C. Next, the remaining water, N-acetyl-L-cysteine, citric acid, and zinc oxide are combined and added to the mixture with stirring. The remaining ingredients are then added with stirring.
The resulting composition is useful for application to the skin for delivering the active and to treat and improve the appearance of the skin.
EXAMPLES IV-V Sunscreening Composition
Sunscreening compositions containing zinc oxide and octyl methoxycinnamate as the active ingredient is prepared by combining the following ingredients using conventional mixing techniques as described above.
Ingredient I II
WT.% WT.%
Octyl methoxycinnamate 6.0 7.5
Zinc Oxide 5.0 10.0
Isohexadecane 4.0 3.0
Glycerin 3.00 5.0
Steareth-2 1.5 2.0
Stearyl alcohol 1.5 1.5
Behenyl alcohol 1.25 1.5
Cetyl alcohol 0.00 2.00
Benzyl alcohol 0.50 0.50
Behenamidopropyl PG dimonium chloride 0.30 1.00
Methyl paraben 0.25 0.25
Propyl paraben 0.15 0.15
Disodium EDTA 0.10 0.10
Water QS 100 QS 100

Claims

1. A leave on skin care composition, comprising:
(A) from 0.001 % to 20% of an active ingredient;
(B) from 1% to 20% of a, hydrophobic, structuring agent selected from the group consisting of saturated C-|6 to C30 fatty alcohols, saturated C-jβ to C30 fatty alcohols containing from 1 to 5 moles of ethylene oxide, saturated C16 to C30 diols, saturated C-|6 to C30 monoglycerol ethers, saturated C-jβ to C30 hydroxy fatty acids, and mixtures thereof, having a melting point of at least 45° C;
(C) from 0.05 % to 10% of a hydrophilic surfactant selected from the group consisting of anionic surfactants, cationic surfactants, zwitterionic surfactants, amphoteric surfactants, and mixtures thereof; and
(D) from 25% to 98.949% water.
2. The composition of Claim 1 wherein the active ingredient is selected from the group consisting of salicylic acid, acetyl salicylic acid, cis-retinoic acid, trans-retinoic acid, N-acetyl-L-cysteine, lipoic acid, azelaic acid, phytic acid, lisophosphotidic acid, tetracycline, ibuprofen, naproxen, acetominophen, hydrocortisone, resorcinol, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4'-trichloro-2'-hydroxy diphenyl ether, 3,4,4'-trichlorocarbanilide, octopirox, 2-phenylbenzimidazole-5- sulfonic acid, dihydroxyacetone, pharmaceutically-acceptable salts thereof, and mixtures thereof.
3. The composition of Claim 1 wherein the active ingredient is selected from the group consisting of salicylic acid, retinoic acid, N-acetyl-L-cysteine, lipoic acid, pharmaceutically-acceptable salts thereof, and mixtures thereof.
4. The composition of Claim 3 wherein the level of active is from 0.01% to 10% by weight of the composition.
5. The composition of Claim 3 wherein the level of active is from 0.025% to 5% by weight of the composition.
6. The composition of Claim 5 wherein the hydrophobic structuring agent is selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmitic acid, polyethylene glycol ether of stearyl alcohol having an average of 2 ethylene oxide units, and mixtures thereof.
7. The composition of Claim 3 wherein the hydrophilic surfactant is a cationic surfactant.
8. The composition of Claim 7 wherein the cationic surfactant has the formula:
Figure imgf000028_0001
wherein R-j, is an alkyl group having from 12 to 30 carbon atoms, or an aromatic, aryl or alkaryl groups having from 12 to 30 carbon atoms; R2, R3, and R4 are independently selected from hydrogen, an alkyl group having from 1 to 22 carbon atoms, or an aromatic, aryl or alkaryl groups having from 12 to 22 carbon atoms; and X is any compatible anion.
9. The composition of Claim 8 wherein the cationic surfactant is selected from the group consisting of dilauryl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, dimyristyl dimethyl ammonium chloride, dipalmityl dimethyl ammonium chloride, and mixtures thereof.
10. The use of a composition in the manufacture of a medicament for the treatment of acne in mammalian skin, said composition comprising:
(A) from 0.001 % to 20% of an active ingredient;
(B) from 1% to 20% of a, hydrophobic, structuring agent selected from the group consisting of saturated C-jβ to C30 fatty alcohols, saturated C-jβ to C30 fatty alcohols containing from 1 to 5 moles of ethylene oxide, saturated C-|6 to C30 diols, saturated C-|6 to C30 monoglycerol ethers, saturated C-jβ to C30 hydroxy fatty acids, and mixtures thereof, having a melting point of at least 45° C; (C) from 0.05 % to 10% of a hydrophilic surfactant selected from the group consisting of anionic surfactants, cationic surfactants, zwitterionic surfactants, amphoteric surfactants, and mixtures thereof; and
(D) from 25% to 98.949% water.
PCT/US1996/010940 1995-06-29 1996-06-26 Stable topical compositions WO1997001326A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP96923465A EP0835095A1 (en) 1995-06-29 1996-06-26 Stable topical compositions
MX9800188A MX9800188A (en) 1995-06-29 1996-06-26 Stable topical compositions.
AU63968/96A AU6396896A (en) 1995-06-29 1996-06-26 Stable topical compositions
JP9504551A JPH11508560A (en) 1995-06-29 1996-06-26 Stable topical composition

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US67395P 1995-06-29 1995-06-29
US60/000,673 1995-06-29
US217095P 1995-08-11 1995-08-11
US60/002,170 1995-08-11
US08/647,083 US5948416A (en) 1995-06-29 1996-05-08 Stable topical compositions
US08/647,083 1996-05-08

Publications (1)

Publication Number Publication Date
WO1997001326A1 true WO1997001326A1 (en) 1997-01-16

Family

ID=27356712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/010940 WO1997001326A1 (en) 1995-06-29 1996-06-26 Stable topical compositions

Country Status (8)

Country Link
US (1) US5948416A (en)
EP (1) EP0835095A1 (en)
JP (1) JPH11508560A (en)
CN (1) CN1209056A (en)
AU (1) AU6396896A (en)
CA (1) CA2225444A1 (en)
MX (1) MX9800188A (en)
WO (1) WO1997001326A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029085A2 (en) * 1996-12-31 1998-07-09 American Medical Research, L.L.C. Skin product having continuing antimicrobial, antiviral, antiseptic, and healing properties
WO2000025732A1 (en) * 1998-11-03 2000-05-11 Bristol-Myers Squibb Company Skin moisturizer compositions containing a sebum control agent
WO2001035912A1 (en) * 1999-11-11 2001-05-25 The Procter & Gamble Company Antidandruff hair conditioning composition
JP2001518886A (en) * 1997-04-03 2001-10-16 ヘンケル・コマンディットゲゼルシャフト・アウフ・アクチエン Oil-in-water emulsion for reconstructing the lamellarity of lipid structure of damaged skin
WO2002002073A3 (en) * 2000-06-30 2002-02-25 Unilever Plc Skin care anti-sebum compositions containing 3,4,4-trichlorocarbanilide
US6645510B1 (en) 1998-06-30 2003-11-11 American Medical Research, Inc. Method of treating topical ailments
US6806250B2 (en) 1999-11-10 2004-10-19 Firmenich Sa Use of fatty alcohol in a perfume composition
US8506940B2 (en) 2003-10-16 2013-08-13 The Procter & Gamble Company Aqueous compositions comprising vesicles having certain vesicle permeability
WO2015164291A1 (en) 2014-04-23 2015-10-29 The Procter & Gamble Company Cosmetic compositions for hydrating skin
EP1803435B1 (en) 2005-12-30 2016-06-08 Henkel AG & Co. KGaA Cosmetic sun protection compositions based on lamelliform emulsions
WO2021130349A1 (en) 2019-12-23 2021-07-01 Kaffe Bueno Aps Cosmetic compositions comprising melanoidins
EP4108094A1 (en) 2021-06-23 2022-12-28 Kaffee Bueno ApS Coffee melanoidin nanoparticles and nanofibers

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221403B1 (en) 1992-08-08 2001-04-24 Seton Healthcare Group Plc Topical composition
JP2000504689A (en) * 1996-02-08 2000-04-18 イー. クリグマン,ダグラス Compositions and methods for performing superficial chemical exfoliation
AU6273299A (en) * 1998-09-30 2000-04-17 Avon Products Inc. Compositions having a sunscreen for use in personal cleansing products
US6503488B1 (en) * 1998-11-17 2003-01-07 Tend Skin International, Inc. Topical compositions including deodorant compositions
US7008963B2 (en) * 1999-07-03 2006-03-07 The William M. Yarbrough Foundation Urushiol induced contact dermatitis solution
CN1088557C (en) * 1999-12-30 2002-08-07 王雪平 Persistent disinfectant and preparation process thereof
US7557235B2 (en) 2000-02-16 2009-07-07 Lubrizol Advanced Materials, Inc. Hydroxyl-terminated thiocarbonate containing compounds, polymers, and copolymers, and polyurethanes and urethane acrylics made therefrom
US20010047039A1 (en) * 2000-04-12 2001-11-29 Mcmanus Richard L. Cationic emulsifier-enhanced liquid crystal gel network based skin care moisturizing compositions
JP4590067B2 (en) * 2000-06-09 2010-12-01 株式会社資生堂 Emulsified composition
US20020153508A1 (en) * 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US6576702B2 (en) 2000-07-20 2003-06-10 Noveon Ip Holdings Corp. Plasticized waterborne polyurethane dispersions and manufacturing process
US6383505B1 (en) 2000-11-09 2002-05-07 Steris Inc Fast-acting antimicrobial lotion with enhanced efficacy
US6733773B1 (en) * 2000-11-21 2004-05-11 Kimberly-Clark Worldwide, Inc. Paper products treated with oil-in-water emulsions
US7195771B1 (en) 2000-11-21 2007-03-27 Kimberly-Clark Worldwide, Inc. Water-soluble lotions for paper products
JP2002284705A (en) * 2001-01-19 2002-10-03 Shiseido Co Ltd Torpent
DE10111039A1 (en) * 2001-03-06 2002-09-12 Beiersdorf Ag Use of active ingredient combinations of alpha-lipoic acid and dermatologically compatible substances which show light absorption in the UV-A range and / or UV-B range for the production of cosmetic or dermatological preparations for the treatment and / or prophylaxis of the symptoms of the intrinsic and / or extrinsic skin aging and for the treatment and prophylaxis of the harmful effects of ultraviolet radiation on the skin
US20040052834A1 (en) * 2001-04-24 2004-03-18 West Bonnie Kay Pre-moistened antibacterial wipe
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
RU2286801C2 (en) 2001-05-01 2006-11-10 Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук Water-absorbing biphase bioadhesive compositions
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
RU2276998C2 (en) 2001-05-01 2006-05-27 Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук Hydrogel compositions
CA2446060A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
CA2449103A1 (en) * 2001-06-01 2002-12-12 Tendskin Company Topical compositions for veterinary uses
US6830746B2 (en) * 2001-09-21 2004-12-14 Playtex Products, Inc. Sunscreen compositions
US7025952B1 (en) 2005-01-31 2006-04-11 Aquea Scientific Corporation Methods of preparation and use of bodywashes containing additives
US7037513B1 (en) 2005-01-31 2006-05-02 Aquea Scientific Corporation Bodywash additives
US6998113B1 (en) 2005-01-31 2006-02-14 Aquea Scientific Corporation Bodywashes containing additives
US20060173709A1 (en) * 2005-01-31 2006-08-03 Traynor Daniel H Bodywash additive business methods
US6897281B2 (en) * 2002-04-05 2005-05-24 Noveon Ip Holdings Corp. Breathable polyurethanes, blends, and articles
US7358295B2 (en) * 2002-04-05 2008-04-15 Lubrizol Advanced Materials, Inc. Hybrid polymer composition, and article therefrom
US6743434B1 (en) 2002-05-14 2004-06-01 Larry D. Lundmark Carbonic emulsion skin care compositions and method for removing chemically bound residues and mineral deposits from hair
CA2484975C (en) * 2002-06-04 2010-04-20 The Procter & Gamble Company Shampoo containing a gel network
US20050209428A1 (en) * 2002-06-19 2005-09-22 Krishnan Tamareselvy Breathable polyurethanes, blends, and articles
US20040167223A1 (en) * 2002-09-03 2004-08-26 Popp Karl F. Topical antibacterial formulations
US20040043946A1 (en) * 2002-09-03 2004-03-04 Popp Karl F. Topical formulations for treatment of skin disorders
US20040171561A1 (en) * 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
US20040241130A1 (en) * 2002-09-13 2004-12-02 Krishnan Tamareselvy Multi-purpose polymers, methods and compositions
US7378479B2 (en) * 2002-09-13 2008-05-27 Lubrizol Advanced Materials, Inc. Multi-purpose polymers, methods and compositions
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
JP2004182639A (en) * 2002-12-03 2004-07-02 Shiseido Co Ltd Skin care preparation composition for external use
US7208144B2 (en) * 2002-12-10 2007-04-24 Cognis Corporation Stabilized dispersion of behenyl alcohol
AU2003100262B4 (en) * 2003-04-07 2003-09-18 Jurox Pty Ltd Stable carprofen composition
US7214391B2 (en) * 2003-06-30 2007-05-08 Usana Health Sciences, Inc. Botanical extract compositions and process for preparing same
CN102764247B (en) 2004-01-30 2016-04-20 考里安国际公司 The rapidly dissolving film of active agent delivery
AU2005271259B2 (en) 2004-08-05 2012-01-19 A.V. Topchiev Institute Of Petrochemical Synthesis Adhesive composition
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US8137754B2 (en) * 2004-08-06 2012-03-20 Lubrizol Advanced Materials, Inc. Hydroxyl-terminated thiocarbonate containing compounds, polymers, and copolymers, and polyurethanes and urethane acrylics made therefrom
EP1786848A1 (en) 2004-08-06 2007-05-23 Noveon, Inc. Polyurethanes and urethane acrylics made from hydroxyl-terminated thiocarbonate containing compounds
US7001592B1 (en) 2005-01-31 2006-02-21 Aquea Scientific Corporation Sunscreen compositions and methods of use
US20080112904A1 (en) * 2005-03-08 2008-05-15 Daniel Henry Traynor Sunscreen Compositions And Methods Of Use
KR101352187B1 (en) * 2005-03-10 2014-02-17 제이알 켐, 엘엘씨 Stable organic peroxide compositions
MX2007010881A (en) * 2005-03-10 2007-12-05 Jr Chem Llc Benzoyl peroxide compositions and methods of use.
US20060222671A1 (en) * 2005-03-30 2006-10-05 Astion Development A/S Dermatological compositions and salts for the treatment of dermatological diseases
US20090306023A1 (en) * 2005-06-29 2009-12-10 Ramirez Jose E Stable organic peroxide compositions
US20070044810A1 (en) * 2005-06-29 2007-03-01 Jr Chem, Llc Method of enhanced drug application
US20070001145A1 (en) * 2005-06-29 2007-01-04 Faryniarz Joseph R Stable organic peroxide compositions
AR054805A1 (en) * 2005-06-29 2007-07-18 Stiefel Laboratories TOPICAL COMPOSITIONS FOR SKIN TREATMENT
US7556820B2 (en) 2005-06-29 2009-07-07 Jr Chem, Llc Stable organic peroxide compositions
US20070027153A1 (en) * 2005-07-27 2007-02-01 Reeth Kevin M Topical skin-protectant and anti-pruritic compositions
US9107844B2 (en) * 2006-02-03 2015-08-18 Stiefel Laboratories Inc. Topical skin treating compositions
US20070203040A1 (en) * 2006-02-24 2007-08-30 Harry Reicherz Bar soap
EP1998742A2 (en) * 2006-03-08 2008-12-10 Nuviance, INC. Transdermal drug delivery compositions and topical compositions for application on the skin
EP1837054B1 (en) * 2006-03-22 2011-06-29 The Procter & Gamble Company Cosmetic composition comprising seabuckthorn
MX2008012526A (en) 2006-03-31 2008-10-14 Stiefel Res Australia Pyt Ltd Foamable suspension gel.
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
DE102006044942A1 (en) * 2006-09-22 2008-04-03 Beiersdorf Ag peeling capsules
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US20080317795A1 (en) * 2007-05-21 2008-12-25 Daniel Henry Traynor Highly charged microcapsules
US8636988B2 (en) * 2008-01-31 2014-01-28 Doctor Essentials Composition for treatment of sunburned skin
US20100263675A1 (en) * 2009-04-21 2010-10-21 Ansell Healthcare Products Llc Condom with Localized Active Agent
JP4406035B1 (en) * 2008-07-09 2010-01-27 株式会社資生堂 Oil-in-water emulsified skin cosmetic
WO2010057117A2 (en) * 2008-11-14 2010-05-20 Helm Pharmaceuticals, Inc. Topical transdermal drug delivery compositions
WO2010083035A2 (en) 2009-01-14 2010-07-22 Corium International, Inc. Transdermal administration of tamsulosin
EP2448416A4 (en) * 2009-06-30 2013-03-20 Univ Columbia Antimicrobial/preservative compositions comprising botanicals
EP2519205A1 (en) * 2009-12-30 2012-11-07 The Procter & Gamble Company Absorbent article comprising lotion composition comprising omega-6 fatty acid
US20110159074A1 (en) * 2009-12-30 2011-06-30 Raphael Warren Wipe Article Comprising Lotion Composition Comprising Omega-6 Fatty Acid And Method Of Improving Skin Barrier Function
US11690793B2 (en) 2012-11-06 2023-07-04 Colabs Int'l Corp. Composition containing a cellulose derived capsule with a sunscreen
US11491088B2 (en) 2012-11-06 2022-11-08 CoLabs International Corporation Compositions containing a capsule with a moisturizing agent
US9456966B2 (en) 2012-11-06 2016-10-04 CoLabs International Corporation Composition containing a cellulose derived capsule with a sunscreen
US11707421B2 (en) 2012-11-06 2023-07-25 Colabs Int'l Corp. Compositions containing a flexible derived capsule with an active agent
US10322301B2 (en) 2012-11-06 2019-06-18 CoLabs International Corporation Compositions containing a cellulose derived capsule with a sunscreen active agent
US11724134B2 (en) 2012-11-06 2023-08-15 CoLabs International Corporation Compositions containing a cellulose derived capsule with a sunscreen active agent
US8936814B2 (en) * 2012-11-30 2015-01-20 Zuri A. Murrell Skin cream
US10111956B2 (en) 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions
EP3813786A4 (en) 2018-06-27 2022-06-29 Colabs International Corporation Compositions comprising silicon dioxide-based particles including one or more agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2594692A1 (en) * 1986-02-27 1987-08-28 Oreal Cleansing composition based on acylisethionate and fatty alcohol
EP0384415A2 (en) * 1989-02-23 1990-08-29 Kao Corporation Hair treatment composition
WO1995003781A1 (en) * 1993-07-03 1995-02-09 The Procter & Gamble Company Personal cleansing compositions
WO1995024179A1 (en) * 1994-03-11 1995-09-14 The Procter & Gamble Company LOW pH, HYDROLYTICALLY STABLE, COSMETIC COMPOSITIONS CONTAINING ACIDIC ACTIVES

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH632668A5 (en) * 1977-12-09 1982-10-29 Hoffmann La Roche COSMETIC AGENT.
US4387090A (en) * 1980-12-22 1983-06-07 The Procter & Gamble Company Hair conditioning compositions
US4877805A (en) * 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US4888342A (en) * 1984-05-16 1989-12-19 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US4732930A (en) * 1985-05-20 1988-03-22 Massachusetts Institute Of Technology Reversible, discontinuous volume changes of ionized isopropylacrylamide cells
US4822604A (en) * 1985-05-20 1989-04-18 S. C. Johnson & Son, Inc. Local treatment of dandruff, seborrheic dermatitis, and psoriasis
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US4960764A (en) * 1987-03-06 1990-10-02 Richardson-Vicks Inc. Oil-in-water-in-silicone emulsion compositions
NZ227994A (en) * 1988-02-16 1990-09-26 Richardson Vicks Inc Skin conditioning composition comprising glycerin and a silicone fluid phase
EP0347145A3 (en) * 1988-06-14 1990-10-24 University Of Utah Research Foundation Heterogeneous interpenetrating polymer networks for the controlled release of drugs
US5118707A (en) * 1990-10-31 1992-06-02 The Procter & Gamble Company Compositions for regulating skin wrinkles comprising a benzofuran derivative
US5073372A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
WO1992013566A1 (en) * 1991-01-31 1992-08-20 Massachusetts Institute Of Technology Interpenetrating-polymer network phase-transition gels
US5229104A (en) * 1991-04-29 1993-07-20 Richardson-Vicks Inc. Artificial tanning compositions containing positively charged paucilamellar vesicles
US5238965A (en) * 1991-05-31 1993-08-24 The Procter & Gamble Company Methods of using lysophosphatidic acids for regulating skin wrinkles
US5296500A (en) * 1991-08-30 1994-03-22 The Procter & Gamble Company Use of N-acetyl-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy
KR950702436A (en) * 1992-07-28 1995-07-29 자코부스 코르넬리스 라세르 PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER
US5411991A (en) * 1992-12-22 1995-05-02 Shander; Douglas Method of reducing hair growth employing sulfhydryl active compounds
DK0693920T3 (en) * 1993-04-16 1998-03-16 Procter & Gamble Compositions to provide artificial sunburn and protect skin from UV radiation
EP0777464A1 (en) * 1994-08-26 1997-06-11 The Procter & Gamble Company Personal cleansing compositions
US5534265A (en) * 1994-08-26 1996-07-09 The Procter & Gamble Company Thickened nonabrasive personal cleansing compositions
US5607980A (en) * 1995-07-24 1997-03-04 The Procter & Gamble Company Topical compositions having improved skin feel
US5733535A (en) * 1995-10-25 1998-03-31 The Procter & Gamble Co. Topical compositions containing N-acetylcysteine and odor masking materials
US5750122A (en) * 1996-01-16 1998-05-12 The Procter & Gamble Company Compositions for treating hair or skin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2594692A1 (en) * 1986-02-27 1987-08-28 Oreal Cleansing composition based on acylisethionate and fatty alcohol
EP0384415A2 (en) * 1989-02-23 1990-08-29 Kao Corporation Hair treatment composition
WO1995003781A1 (en) * 1993-07-03 1995-02-09 The Procter & Gamble Company Personal cleansing compositions
WO1995024179A1 (en) * 1994-03-11 1995-09-14 The Procter & Gamble Company LOW pH, HYDROLYTICALLY STABLE, COSMETIC COMPOSITIONS CONTAINING ACIDIC ACTIVES

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 119, no. 14, 4 October 1993, Columbus, Ohio, US; abstract no. 141638, L. DAI: "Preparation of oil-in-water miniemulsions from long-chain fatty alcohols." XP002018353 *
L. DAI, YINGYONG HUAXUE, vol. 10, no. 3, 1993, BEIJING (CHINA), pages 57-59 *
R. J. GOETZ: "Dilute Phase Behavior of Cetyl Alcohol, Sodium Lauryl Sulfate, and Water", LANGMUIR, vol. 6, 1990, pages 132 - 136, XP002018352 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645507B2 (en) 1996-12-31 2003-11-11 American Medical Research, Inc. Skin product having continuing antimicrobial, antiviral, antiseptic, and healing properties
WO1998029085A3 (en) * 1996-12-31 1999-04-22 American Med Res Llc Skin product having continuing antimicrobial, antiviral, antiseptic, and healing properties
WO1998029085A2 (en) * 1996-12-31 1998-07-09 American Medical Research, L.L.C. Skin product having continuing antimicrobial, antiviral, antiseptic, and healing properties
JP2001518886A (en) * 1997-04-03 2001-10-16 ヘンケル・コマンディットゲゼルシャフト・アウフ・アクチエン Oil-in-water emulsion for reconstructing the lamellarity of lipid structure of damaged skin
US6645510B1 (en) 1998-06-30 2003-11-11 American Medical Research, Inc. Method of treating topical ailments
WO2000025732A1 (en) * 1998-11-03 2000-05-11 Bristol-Myers Squibb Company Skin moisturizer compositions containing a sebum control agent
US6806250B2 (en) 1999-11-10 2004-10-19 Firmenich Sa Use of fatty alcohol in a perfume composition
WO2001035912A1 (en) * 1999-11-11 2001-05-25 The Procter & Gamble Company Antidandruff hair conditioning composition
US6979439B1 (en) 1999-11-11 2005-12-27 The Procter & Gamble Company Antidandruff hair conditioning composition
WO2002002073A3 (en) * 2000-06-30 2002-02-25 Unilever Plc Skin care anti-sebum compositions containing 3,4,4-trichlorocarbanilide
US8506940B2 (en) 2003-10-16 2013-08-13 The Procter & Gamble Company Aqueous compositions comprising vesicles having certain vesicle permeability
EP1803435B1 (en) 2005-12-30 2016-06-08 Henkel AG & Co. KGaA Cosmetic sun protection compositions based on lamelliform emulsions
WO2015164291A1 (en) 2014-04-23 2015-10-29 The Procter & Gamble Company Cosmetic compositions for hydrating skin
WO2021130349A1 (en) 2019-12-23 2021-07-01 Kaffe Bueno Aps Cosmetic compositions comprising melanoidins
EP4108094A1 (en) 2021-06-23 2022-12-28 Kaffee Bueno ApS Coffee melanoidin nanoparticles and nanofibers
WO2022268898A1 (en) 2021-06-23 2022-12-29 Kaffe Bueno Aps. Coffee melanoidin nanoparticles and nanofibers

Also Published As

Publication number Publication date
AU6396896A (en) 1997-01-30
MX9800188A (en) 1998-04-30
US5948416A (en) 1999-09-07
CN1209056A (en) 1999-02-24
EP0835095A1 (en) 1998-04-15
JPH11508560A (en) 1999-07-27
CA2225444A1 (en) 1997-01-16

Similar Documents

Publication Publication Date Title
US5948416A (en) Stable topical compositions
MXPA98000188A (en) Topic compositions es
AU702897B2 (en) Low pH, hydrolytically stable, cosmetic compositions containing acidic actives
AU706920B2 (en) Compositions for topical delivery of active ingredients
AU706358B2 (en) Topical compositions having improved skin feel
AU725142B2 (en) Photoprotective compositions
US5989536A (en) Personal cleansing compositions containing alkoxylated ether and cationic ammonium salt for deposition of active agent upon the skin
EP0714283B1 (en) Personal cleansing compositions
US6153176A (en) Low pH sunscreen compositions
CZ20004708A3 (en) Mixture suitable for use as suntan cream
US20210030646A1 (en) An antimicrobial composition comprising essential oil and antimicrobial lipid
WO1997023594A1 (en) Cleansing compositions
WO1999024010A1 (en) Compositions containing combinations of solid polyol fatty acid polyesters and a solid oil
CZ20014706A3 (en) Cosmetic method of skin care
WO2023151986A1 (en) A skin brightening composition

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96196208.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN CZ JP KR MX

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996923465

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2225444

Country of ref document: CA

Ref document number: 2225444

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1997 504551

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/000188

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1996923465

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996923465

Country of ref document: EP